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ABSTRACT 
Jennifer L. Moss: Concomitant Adolescent Vaccination: The Influence of Seasonal 
Variation, School Requirements, and Patient-Provider Communication 
(Under the direction of Noel T. Brewer) 
Introduction. Human papillomavirus (HPV) vaccination has the potential to prevent 
thousands of cases of anogenital cancers each year, but coverage falls short of national goals. 
Other vaccines recommended for adolescents (tetanus, diphtheria, and pertussis (Tdap) 
booster and meningococcal vaccine) have much higher coverage. Administering HPV 
vaccine with other adolescent vaccines concomitantly (i.e., at the same healthcare visit) could 
improve HPV vaccine coverage. This dissertation examined factors likely to influence 
concomitant uptake, namely, seasonal variation in vaccination, vaccination school entry 
requirements, and patient-provider communication style. 
Methods. Data came from 99,921 participants in the 2008 to 2012 versions of the 
National Immunization Survey (NIS)-Teen. Each year, NIS-Teen gathers data on about 
20,000 adolescents (ages 13–17) using telephone interviews administered to parents and 
written questionnaires mailed to healthcare providers to verify vaccination. In the first study, 
I used the Edwards method to examine the annual, seasonal cycles in uptake of individual 
vaccines and concomitant vaccination. In the second study, I conducted longitudinal 
mediation analysis with bootstrapping to test the attenuating effects of these cycles on the 
relationship between states’ vaccination school entry requirements and coverage rates. In the 
third study, I analyzed the interaction between vaccination school entry requirements and 
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providers’ communication style in their relationship with adolescents’ uptake of individual 
vaccines and concomitant vaccination. 
Results. Uptake of individual vaccines was 5–10 times as common, and concomitant 
vaccination was 3–6 times as common, at the peaks of the seasonal cycles compared to their 
troughs (all p<.001). States with vaccination school entry requirements had more extreme 
vaccination cycles than other states and higher coverage rates for both the vaccines targeted 
by the requirements (more than 20% higher) and the other adolescent vaccines (6–18% 
higher) (all p<.001). However, contrary to my hypothesis, vaccination cycles did not mediate 
the relationship between states’ school entry requirements and coverage. Regardless of 
states’ vaccination school entry requirements, uptake of individual vaccines was higher when 
parents reported that providers used a more collaborative communication style (all p<.05), 
but concomitant vaccination did not vary by providers’ communication style.  
Conclusion. Concomitant vaccination is more common in the summer months, 
especially in states with policies requiring students to receive one or more adolescent 
vaccines prior to school entry. Patient-provider communication was less influential for 
concomitant vaccination than for receipt of individual vaccines. To increase HPV vaccination 
(individual or concomitant administration), quality improvement and health promotion 
activities should precede summer peaks and the implementation of new school entry 
requirements. 
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CHAPTER 1: OVERVIEW AND SPECIFIC AIMS 
Human papillomavirus (HPV) vaccine is effective and safe.1-3 Widespread uptake 
among adolescents now could prevent thousands of cases of cervical, vaginal, vulvar, anal, 
and other cancers in the years to come.1,4 National guidelines recommend that all 11- and 12-
year-olds in the United States receive 3 doses of HPV vaccine.1 As of 2012, only 54% of 
adolescent girls had received at least one dose (i.e., vaccine initiation), and improvements in 
HPV vaccination have stalled in recent years.5 The CDC suggests that to increase HPV 
vaccine coverage, clinicians should administer HPV vaccine at visits at which they 
administer other adolescent vaccines such as the tetanus, diphtheria, and pertussis (Tdap) 
booster vaccine.1 For this dissertation, I will use the term concomitant vaccination to refer to 
administration of HPV and Tdap vaccines during the same healthcare encounter. Tdap 
vaccine has an overall higher level of uptake than HPV vaccine, and 43 states require that 
adolescents receive Tdap prior to entering middle or high school. Linking HPV vaccination 
with receipt of Tdap could improve population-level coverage with HPV vaccine. 
To date, research on adolescent vaccination has focused on intrapersonal factors 
including knowledge, attitude, and use of other preventive healthcare services. Higher-level 
factors that influence Tdap, HPV, and concomitant vaccination remain understudied. For 
instance, only a few studies have examined the effects of school entry requirements for Tdap 
vaccination on adolescent vaccination coverage, and no studies have investigated the effect 
of school entry requirements for HPV vaccine. Another important but unstudied higher-level 
factor is the yearly cycle in demand for vaccination. A preliminary investigation in North 
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Carolina found that over the past several years, healthcare providers delivered two times as 
many doses of HPV vaccine and almost five times as many doses of Tdap in August 
compared to December, and anecdotal evidence suggests that these summertime peaks in 
adolescent vaccination occur nationally. A third understudied factor is interpersonal 
communication style employed by healthcare providers when discussing vaccines with 
patients and parents. A provider’s recommendation is one of the strongest correlates of 
vaccination behaviors,6 but little research has investigated recommendation style. Over the 
past few decades, healthcare practice has moved toward a collaborative decision-making 
model emphasizing joint communication between patient and provider, but emerging 
research suggests that a more directive approach to recommending vaccines results in higher 
levels of uptake. Understanding the influence of these factors could help public health 
researchers identify effective policy-level interventions, highlight periods during which 
promotion programs could be most efficient, and offer guidance for clinical practice.  
The proposed dissertation will investigate the influence of these multilevel factors on 
HPV vaccination and cancer prevention. The research described in the following chapters 
focuses on HPV vaccine initiation (i.e., receipt of at least one dose) among adolescent 
females because the analysis uses a dataset capturing this behavior in this population over 
five years. An important mechanism for this research is concomitant vaccination (i.e., uptake 
of multiple vaccines at the same healthcare visit), which explicitly links uptake of HPV and 
Tdap vaccines. The dissertation project has two specific aims.  
Aim 1. Quantify Cycles in Adolescent Vaccination 
The first aim is to investigate the relationship between yearly cycles in vaccine 
demand and state-level HPV vaccination rates. This aim will quantify the extent to which 
3 
Tdap, HPV, and concomitant vaccination peaks in the summer months in all U.S. states. In 
addition, this aim will test the relationship between the magnitude of yearly peaks in Tdap, 
HPV, and concomitant vaccination and state-level vaccination rates. Finally, this aim will 
establish whether summer peaks in concomitant vaccination mediate the relationship between 
school entry requirements for Tdap and HPV vaccine coverage. 
Aim 2. Determine the Effect of Collaborative Patient-Provider Communication on 
Adolescent Vaccination 
The second aim is to determine how dimensions of collaborative decision making 
influence vaccination. This aim will determine whether collaborative information exchange, 
deliberation, and decisions correlate with increased uptake of adolescent vaccines and 
concomitant vaccination. In addition, this aim will examine whether this relationship varies 
by the presence of school entry requirements. 
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CHAPTER 2: LITERATURE REVIEW 
In this chapter, I summarize background information on human papillomavirus 
(HPV) vaccine, including the public health significance of HPV vaccination, patterns of 
adolescent vaccination in the United States, and vaccine legislation. This review of the 
literature focuses on issues surrounding HPV vaccine initiation (i.e., receipt of at least one 
dose) among adolescent females. Although national guidelines recommend that both male 
and female adolescents receive HPV vaccine, the proposed research will focus on five years 
of data on vaccination among adolescent females. The recommendation for males is more 
recent than the recommendation for females. In addition, data on males are not available for a 
long enough period of time, and vaccination remains infrequent enough in all years except 
the most recent, to give reliable estimates at the state level.  
Public Health Significance of HPV Vaccination 
Sustained infection with human papillomavirus (HPV) causes several cancers, 
including anal, cervical, oral, penile, vaginal, and vulvar cancers.7,8 These cancers cause 
significant morbidity and mortality. For example, each year in the United States, almost 
11,000 women are diagnosed with and more than 4,000 women die from, cervical cancer.8 
More than 99% of these cases are attributable to HPV infection.8,9 Annually, HPV-associated 
cancers result in thousands of deaths and $3.7 billion in lost lifetime productivity in the 
United States, disproportionately burdening young women.10 
HPV is the most common sexually transmitted infection.7 Although prevalence 
among older women is low, rates among younger women are high: 25% among 14- to 19-
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year-old women and 45% among 20- to 24-year-old women.11,12 For most women who 
contract HPV, their first infection occurs within a year of sexual debut.13 About 90% of HPV 
infections resolve within two years of infection,7 but persistent infection with high-risk 
subtypes of HPV can lead to cancer. For example, two strains of HPV, types 16 and 18, 
cause 70% of cervical cancer cases.14 Estimates of the prevalence of these subtypes in U.S. 
women range from 2% to 18% (HPV 16) and from <1% to 5% (HPV 18).11 
In 2006, the Food and Drug Administration (FDA) licensed the first prophylactic 
vaccine to protect against infection with HPV, and now two HPV vaccines are available.15 
Both three-dose vaccines protect against HPV 16 and HPV 18.1 National guidelines 
recommend routine administration of HPV vaccine to 11- to 12-year-old adolescents.15 
Studies of the effectiveness and safety of HPV vaccine report promising results. Although the 
long-term effects of the vaccine in reducing the incidence of HPV-attributable cancers are as 
yet unknown, vaccination is associated with striking reductions in HPV infection,16-19 genital 
warts,3,16,19 and lesions that may develop into cancer.16,19 In Australia, which implemented a 
nationalized HPV vaccination program in 2007, population-based estimates of the prevalence 
of genital warts among women under age 21 dropped from 12% in 2007 to <1% in 2011.3 
Numerous large-scale safety monitoring studies have found no evidence for increased risk of 
adverse events associated with receiving the vaccine.2,20,21 
Despite the demonstrated effectiveness and safety of HPV vaccine, uptake among 
adolescents in the United States remains low. As of 2012, only 54% of adolescent girls had 
initiated HPV vaccine (i.e., received at least one dose).5 Other countries have achieved high 
levels of HPV vaccination among the target age group, with rates of completion (i.e., receipt 
of three doses) exceeding 70%.22-24 These suboptimal levels of HPV vaccination in the 
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United States leave millions of young people at risk for HPV infection, genital warts, and 
HPV-associated cancers. 
Adolescent Vaccination in the United States 
In addition to HPV vaccine, the routine adolescent vaccine platform in the United 
States includes the tetanus, diphtheria, and pertussis (Tdap) booster vaccine and 
meningococcal vaccine.15 Since the introduction of these vaccines, Tdap and meningococcal 
vaccination coverage has increased steadily. However, recent surveillance data suggest that 
improvements in HPV vaccination coverage have slowed.25,26 In 2012, coverage of Tdap and 
meningococcal vaccination reached 85% and 74%, respectively, figures that are 20 to 30 
percentage points higher than the estimate for HPV vaccine initiation among adolescent 
females (54%).5 Figure 1 illustrates the widening gap between adolescents’ coverage levels 
for Tdap and meningococcal vaccine versus HPV vaccine. 
The U.S. Department of Health and Human Services released performance objectives 
for Tdap, meningococcal, and HPV vaccination as part of the Healthy People 2020 initiative. 
The three objectives set a benchmark for 80% of 13- to 15-year-old adolescents to complete 
each vaccine (for HPV vaccine, among girls only).27 As of 2012, vaccine coverage rates for 
this age group were 85% (Tdap booster vaccine), 74% (meningococcal vaccine), and 28% 
(HPV vaccine completion).5 Thirty-six states met the Healthy People 2020 goal for Tdap 
vaccination, 12 met the goal for meningococcal vaccination, and none met the goal for HPV 
vaccination.5 These data suggest that uptake of HPV vaccine is too low, while uptake of 
other recommended adolescent vaccines is closer to levels that achieve public health goals. 
National estimates for adolescent vaccination coverage mask wide variation in uptake 
by state. Among 13- to 17-year-old adolescents in 2012, statewide coverage with Tdap 
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ranged from 54% in Mississippi to 96% in New Hampshire. Statewide coverage with 
meningococcal vaccine ranged from 38% in Arkansas to 94% in Rhode Island. Coverage 
with at least one dose of HPV vaccine among adolescent females ranged from 39% in Florida 
to 74% in Rhode Island, and coverage with all three doses ranged from 12% in Mississippi to 
58% in Rhode Island.5 These 35 to 56 percentage point differences in uptake by state dwarf 
those based on other important characteristics such as adolescent’s race/ethnicity or poverty 
status, which generally demonstrate differences of less than 10 percentage points.5 
Inadequate and variable uptake of adolescent vaccines occurs partially as a 
consequence of lower use of preventive healthcare services among adolescents in the United 
States.28 Although the American Academy of Pediatrics recommends annual preventive 
check-ups for young people up to age 21,29 a recent national study found that fewer than half 
of 10- to 17-year-old adolescents had attended a preventive healthcare visit in the previous 
year.30 In response to these trends, the CDC recommends that healthcare providers administer 
adolescent vaccines at all eligible visits (i.e., preventive and sick visits) and administer 
multiple vaccines during the same visit (i.e., concomitant vaccination).1 Concomitant 
vaccination is safe and produces comparable immune responses to instances of vaccination at 
separate healthcare encounters.31 Using these two techniques to reduce missed opportunities 
for vaccination could be incredibly effective in increasing uptake of adolescent vaccines, 
especially for HPV vaccine. Stokley and colleagues25 reported that eliminating missed 
opportunities (defined as any type of healthcare visit at which an eligible female adolescent 
received at least one other vaccine but not HPV vaccine) would result in 93% coverage with 
at least one dose of HPV vaccine among adolescent females, an estimate almost 40 
percentage points higher than the current level of coverage.5  
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In summary, patterns of adolescent vaccination differ by vaccine and by state. That 
adolescents often forego their recommended preventive check-ups is a challenge to efforts to 
improve vaccination rates, but minimizing missed opportunities for vaccine administration 
could increase coverage among adolescents who eventually interact with the healthcare 
system.  
Legislating Adolescent Vaccination 
An alternative solution to the problem of adolescents’ poor use of preventive check-
ups is to adopt new regulations, such as a state policy requiring that adolescents receive 
vaccinations before entering a certain grade in public school. For example, North Carolina 
has a policy requiring students to receive Tdap prior to entering sixth grade, but the state 
does not have a policy requiring HPV vaccination. School entry requirements are highly 
effective in improving rates of vaccine uptake.32-34 
Much discussion in the media and in research literature has considered the 
constitutionality and ethics of school entry requirements and whether they needlessly reduce 
individuals’ autonomy in making healthcare decisions for themselves or their children. 
According to legal precedent, school entry requirements are constitutional as long as (1) they 
address a public health necessity by preventing disease, (2) they involve a vaccine that has a 
demonstrated effect on preventing the disease it targets, (3) receipt of the vaccine is not 
overly burdensome, and (4) they are approved by the legislature.35 Authors have argued that 
school entry requirements are ethical,32,33,36 although all of these articles note that exemptions 
from school entry requirements are necessary for medical and perhaps philosophical reasons.  
Most of the United States currently has school entry requirements for at least one 
adolescent vaccine. Across the 50 states and Washington D.C., 43 jurisdictions had school 
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entry requirements for Tdap that were effective by Fall 2012, 16 had requirements for 
meningococcal vaccine, and 2 had requirements for HPV vaccine.37 School entry 
requirements for HPV vaccine have faced considerable resistance from the general public 
and from legislators. In 2007, the first year after the CDC recommended HPV vaccine for 
routine use in adolescent females, 24 states introduced legislation for school entry 
requirements, but 22 of these states did not adopt the proposed policies, in part because the 
public became aware that advocacy for the policies was funded by Merck, who makes HPV 
vaccine.38 Since then, only a handful of state legislatures have debated school entry 
requirements for HPV vaccine. Schwartz and colleagues39 argue that the initial enthusiasm 
for HPV vaccine plummeted when states began considering school entry requirements 
because the public believed the vaccine was too new and potentially unsafe; however, other 
factors, such as drug company involvement, negative media attention, and concerns about 
vaccine cost, may have also contributed to the relative unpopularity of HPV vaccine 
requirements versus requirements for Tdap and meningococcal vaccines. Though years have 
passed since the introduction of HPV vaccine, public health officials and providers remain 
wary of HPV vaccine school entry requirements,40,41 despite parental support being quite 
high for HPV vaccination policies that allow parents to exempt their child from the 
requirement.42,43  
The promise of HPV vaccine school entry requirements is tempered by the potential 
detrimental effects of the generous exemption provisions needed to make such a policy 
politically feasible. For instance, Reiter and colleagues42 found that among parents who 
intended to vaccinate their adolescent sons, about 50% more parents would consent to 
vaccination given a policy requiring active permission for the child to receive the vaccine 
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than would consent to vaccination given a policy requiring active refusal for the child to 
receive an exemption from vaccination (75% versus 52%). However, generous opt-out 
provisions could theoretically weaken the default effect described above by diluting the 
implied message from policymakers, reducing the effort needed to opt-out of the default, 
and/or changing the reference point from which parents evaluate vaccination decisions. The 
rate at which parents seek exemptions for their children appears to be rising,44 driven in part 
by public doubt about the safety of vaccines.45,46 
States that have implemented school entry requirements for adolescent vaccines have 
higher rates of vaccine uptake than states without such policies. For example, Tdap coverage 
levels are 10 percentage points higher in states with Tdap school entry requirements than 
states without them.47 School entry requirements likely increase vaccination rates by 
establishing a default for a health behavior.48,49 Johnson and Goldstein48 demonstrated that a 
default, or a “condition … imposed when an individual fails to make a decision” (p. 1338), 
increases the rates at which people engage in the target behavior. Three mechanisms 
contribute to the creation of a default effect:48 (1) individuals may interpret a default behavior 
as a suggestion from policymakers, thereby changing perceived norms in support of the 
behavior; (2) engaging in the default behavior often requires less effort than an alternative 
behavior; and (3) because individuals evaluate the pros and cons of alternative behaviors in 
reference to the default behavior, acting against the default may seem unappealing due to the 
psychological phenomenon of loss aversion.50  
In the context of school entry requirements, uptake of the targeted vaccine is similar 
to a default behavior. These policies reflect explicit recommendations from policymakers and 
health authorities (suggestion, explanation 1 above). Parents wishing to forego vaccination 
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must file waivers justifying their child’s exemption (effort, explanation 2 above). Finally, 
parents evaluate the alternative behavior (i.e., not vaccinating) in reference to the default of 
vaccinating, and the relative losses of exempting from vaccination versus getting a vaccine 
may not seem worthwhile (loss aversion, explanation 3 above). The effort explanation may 
be less relevant to vaccination because both options, seeking or foregoing vaccination, 
require effort.  
Additionally, studies have demonstrated that Tdap school entry requirements are 
associated with increased uptake of both meningococcal vaccine51 and HPV vaccine.52 This 
carry-over effect is not well understood, but presumably it occurs via concomitant 
administration of the non-targeted vaccines when adolescents seek Tdap. Dempsey and 
colleagues52 described other potential explanations for this carry-over effect, including 
increased demand for and availability of all adolescent vaccines in states with school entry 
requirements, improved office procedures that facilitate carry-over vaccination, and 
normalization of adolescent vaccination. For parents in states with school entry requirements, 
the suggestion and loss aversion explanations of the default effect described previously could 
generalize from Tdap to the non-targeted vaccines. That is, parents could perceive 
endorsements from policymakers and health authorities not just for Tdap but for all 
adolescent vaccines (similar to Dempsey’s normalization explanation), or they may extend 
the potential losses of refusing Tdap (e.g., leaving an adolescent at risk for communicable 
disease) to the losses of refusing a non-targeted vaccine. 
In conclusion, school entry requirements for adolescent vaccination can be effective 
in increasing rates of uptake. Requirements for childhood and selected adolescent vaccines 
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are associated with higher coverage with targeted vaccines, with smaller, carry-over effects 
on other vaccines.  
Conclusion 
Widespread uptake of HPV vaccine could prevent thousands of cases of cancer in the 
coming decades. Coverage with HPV vaccine among adolescent females in the United States 
varies among states but overall is too low, especially compared to levels of uptake for Tdap 
and meningococcal vaccines. Routine concomitant vaccination with both Tdap and HPV 
vaccines during the same healthcare encounter could greatly improve rates of HPV 
vaccination. School entry requirements for Tdap successfully increase coverage with HPV 
vaccine through a carry-over effect. However, more research is needed on how these 
variables relate to each other. 
 
Figure 1. Vaccine coverage among U.S. adolescents ages 13 to 17. (Source: National 
Immunization Survey (NIS)-Teen.) 
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CHAPTER 3: ANNUAL CYCLES IN ADOLESCENT VACCINATION 
Few studies have moved beyond the individual person or healthcare encounter to 
examine the role of population-level patterns in adolescent vaccination. Anecdotal evidence 
suggests that more adolescents seek vaccines during summer months than during the rest of 
the year. The timing of healthcare providers’ interactions with adolescents to administer 
vaccines has important implications for healthcare practice and future interventions. In this 
chapter, I will examine the effect of annual cycles in adolescent vaccination on overall levels 
of vaccine coverage. I introduce the literature on cyclical effects in health outcomes, report 
preliminary results of an investigation of cyclical trends in adolescent vaccination in one 
state, present the conceptual model for Aim 1, describe the analytic methods, and summarize 
the implications of annual cycles for healthcare practice and public health. 
Cyclical Effects in Public Health 
Many health behaviors demonstrate cyclical patterns, including cycles that recur 
yearly (e.g., increased incidence of suicide during the summer months53), monthly (e.g., more 
substance abuse during the first week of each month54), and weekly (e.g., increased internet 
searches for smoking cessation information on Mondays55). Much of the research on cyclical 
effects focuses on trends in mortality, which demonstrates an increase in the winter months 
relative to the summer months.56 Studies of cyclical effects often highlight the causal 
influence of environmental factors such as air quality, heat, or insect activity,56-59 but other 
studies find relationships that may be attributable to social factors that affect health such as 
isolation, school stress, or resolutions to change.53-55,60  
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Anecdotal evidence suggests that the demand for adolescent vaccination increases 
during the summer months, but no research studies have examined this phenomenon. 
Logically, at least two social factors may contribute to a summer peak in vaccination. First, 
most adolescent children do not attend school during the summer months. Thus, to the extent 
that parents view taking children out of school to seek healthcare as a barrier to vaccination, 
visiting a provider during the summer months may be associated with reduced perceived 
barriers and increased ease of vaccination relative to visiting a provider throughout the rest of 
the year. Second, some families living in states with school entry requirements for certain 
vaccination(s) may not be motivated to seek them until just before the beginning of the 
targeted school year.  
Preliminary Study on Cyclical Effects in Vaccination  
In a preliminary study of vaccination trends in North Carolina, we found evidence of 
an annual cycle with a peak in the summer (Figure 2). Averaged over 2008 to 2012, 
healthcare providers across North Carolina administered twice as many doses of HPV 
vaccine and almost five times as many doses of Tdap each August compared to December. 
This descriptive summary of the monthly vaccination patterns does not allow for inferential 
analysis but instead establishes preliminary evidence of cyclical vaccination trends in one 
state. 
Notably, North Carolina has had a school entry requirement for Tdap since Fall 2008, 
targeting adolescents entering sixth grade; however, the state does not have a school entry 
requirement for HPV vaccination. The Tdap requirement likely contributes to the more 
dramatic peak in Tdap than HPV vaccination evidenced by these data. The peak in uptake of 
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HPV vaccine probably emerges due to concomitant vaccination during a summertime visit at 
which an adolescent received Tdap. 
Not pictured in Figure 2 is the cycle in concomitant vaccination, that is, instances 
when adolescents received both Tdap and HPV vaccines during the same healthcare 
encounter. Concomitant vaccination may peak in the summer due to the increased numbers 
of adolescents receiving each individual vaccine. As described above, the CDC recommends 
that providers administer both doses at the same healthcare encounter to optimize adolescent 
vaccination.1 A cycle in concomitant vaccination may explain the carry-over effect of state 
vaccine school entry requirements on other vaccines described above. That is, a dramatic 
increase in the number of adolescents receiving Tdap and HPV vaccines concomitantly 
during the summer could explain the elevated HPV vaccine coverage levels in states with 
Tdap school entry requirements. 
Conceptual Model and Hypotheses 
The conceptual model in Figure 3 summarizes the main relationships of interest in the 
proposed research for Aim 1. In brief, this aim will involve (1) replication of the finding that 
school entry requirements are associated with increased coverage of adolescent vaccination, 
(2) examination of cycles in adolescent vaccination, and (3) a test of the mediational effect of 
cyclical effects in concomitant vaccination on the relationship between Tdap school entry 
requirements and states’ HPV vaccine coverage. 
In Aim 1, I will examine four main constructs. State cycles of vaccination captures 
the presence and magnitude of a cyclical effect in adolescent vaccination for Tdap or HPV 
vaccine, or both vaccines concomitantly; details on measurement of cycles of vaccination 
appear in the next section. School entry requirements indicates whether a state had a policy 
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requiring Tdap or HPV vaccination prior to school entry in effect by fall of a given year. 
Finally, state vaccine coverage reflects the proportion of adolescents in a state who had 
received Tdap or HPV vaccine for each year under study. I describe more fully the proposed 
relationships among these variables in the hypotheses below. 
Hypothesis 1a. States with Tdap school entry requirements will have higher vaccine 
coverage for Tdap and HPV vaccines than states without Tdap school entry requirements. 
As described previously, research has already established that more adolescents 
receive Tdap47 and HPV vaccine52 in states with Tdap school entry requirements. I will test 
this relationship using a nationally representative dataset including observations from 2008 to 
2012. 
Hypothesis 1b. States with HPV vaccine school entry requirements will have higher 
HPV vaccine coverage than states without HPV vaccine school entry requirements. 
[Exploratory hypothesis] 
Only two jurisdictions, Virginia and Washington D.C. (called “states” for simplicity), 
currently have HPV vaccine school entry requirements. Previous literature demonstrates that 
school entry requirements are associated with increased rates of uptake for targeted 
vaccines.32,34,47 I will conduct an exploratory analysis to examine whether HPV vaccine 
coverage is higher in states with school entry requirements than in other states. 
Hypothesis 1c. Nationally and within each state, monthly Tdap and HPV vaccination 
will peak in the summer (i.e., July, August, or September), as will concomitant administration 
of the two vaccines. 
Our preliminary investigation in North Carolina found evidence for dramatic yearly 
cycles in adolescent vaccination during the summer months compared to the winter months 
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(see Figure 2). Anecdotal evidence from physicians, colleagues at the CDC, and a vaccine 
manufacturer suggests that this pattern occurs across the United States.  
Hypothesis 1d. State cycles of concomitant vaccination will mediate the positive 
association between Tdap school entry requirements and HPV vaccine coverage. 
As described previously, states with Tdap school entry requirements have higher 
levels of HPV vaccination among their adolescent female populations than states without 
such policies.52 I propose that cycles in concomitant vaccination mediate this relationship. 
School entry requirements likely exaggerate cyclical effects of adolescent vaccination, such 
that the peaks of vaccination (for Tdap, HPV, and concomitant vaccination) that occur in the 
summer become larger. The increased volume of adolescents receiving concomitant 
vaccination with both Tdap and HPV vaccine during the summer could explain the carry-
over effect of the Tdap policy onto a non-targeted vaccine. 
Proposed Analytical and Statistical Methods 
Data Sources 
The proposed study analyzed national data to examine adolescent vaccination 
between 2008 and 2012. To test the hypotheses described previously, I analyzed data from 
three sources: the National Immunization Survey-Teen (NIS-Teen), the Immunization Action 
Coalition’s (IAC) database of vaccine school entry requirements, and the CDC’s estimates of 
state-level adolescent vaccine coverage. 
The CDC, the National Center for Immunization and Respiratory Disease, and the 
National Center for Health Statistics have administered NIS-Teen each year since 2008.61 
NIS-Teen has two parts: (1) telephone interviews with caregivers (“parents”) to assess 
adolescents’ vaccination history, and (2) verification by healthcare providers of adolescents’ 
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vaccination history (i.e., vaccinations recorded in a patient’s record as having been delivered 
at that clinic or at another clinic). At the beginning of the survey, interviewers obtained 
verbal consent and sought additional consent from parents to contact the adolescent’s 
primary healthcare provider. Each year’s data originated from a nationally representative 
sample of parents of 13- to 17-year-old adolescents. Sampling frames for survey years 2008 
through 2010 were U.S. landline phone numbers; beginning in 2011, the CDC expanded the 
sampling frame to include cell phone numbers. Each year, the CDC sent invitation letters to a 
sample of eligible participants, and parents from more than 80% of contacted households 
completed the survey. On average, 9,350 adolescent girls had provider-verified data on 
vaccination each year, for an estimated total of more than 45,000 participants. The CDC 
releases survey weights for the data; using these weights may increase the generalizability of 
vaccination estimates.61 
The IAC compiles data from state health departments on school entry requirements 
for vaccination, including whether each state has a Tdap requirement and, if so, when it 
became effective.37 I also used the IAC database to gather data on HPV vaccine 
requirements. 
The CDC uses NIS-Teen to calculate each state’s vaccination coverage among 13- to 
17-year-olds, published annually in Morbidity and Mortality Weekly Report (MMWR).5,62-65 
The sample I used in Aim 1 and the sample used in MMWR estimates are identical. I 
calculated uptake of Tdap and HPV vaccine initiation as a preliminary step to confirm that 
my approach yielded the same estimates of states’ coverage as those reported in MMWR. 
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Measures 
This study examined HPV vaccine initiation (i.e., receipt of at least one dose, 
hereafter referred to as “HPV vaccination” for the sake of simplicity) and receipt of Tdap 
vaccine. I captured monthly vaccination and cycles of vaccination with items on the provider 
survey in NIS-Teen that reflect the date that each participating adolescent female received 
Tdap and HPV vaccine. I classified instances in which Tdap and HPV vaccination occurred 
on the same date as concomitant vaccination. Analyses used aggregated data that reflect the 
weighted number of adolescent girls receiving vaccines each month from 2008 to 2012, 
separately for each state and Washington D.C. (n=51, hereafter referred to as “states” for 
simplicity).  
I measured school entry requirements using dichotomous indicator variables for the 
presence of a Tdap or HPV vaccine requirement in effect by the fall of each year.  
Finally, I measured state vaccine coverage with the CDC’s annual estimates of the 
proportions of 13- to 17-year-old adolescents in each state that had received Tdap and HPV 
vaccines. 
Data Preparation 
I created monthly counts of adolescents vaccinated for each year and averaged across 
years (e.g., January data will be the average of that month in 2008, 2009, 2010, 2011, and 
2012). Vaccination could have occurred at any time previous to the participant’s NIS-Teen 
interview; thus, this surveillance system accumulates more doses administered in earlier 
years than in later years. To ensure that each year contributes equally to the overall cycle, I 
applied weights to each year’s monthly counts equal to the inverse probability of a 
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vaccination being reported in that year. I divided doses delivered per month by the number of 
days in the month to reduce the influence of month length. 
The dependent variable in these analyses, state vaccine coverage, was a proportion 
and therefore did not meet the statistical assumptions required for linear regression 
analysis.66 To increase the linearity of this variable to meet the statistical assumptions of 
linear regression analysis, I transformed the proportion prior to analysis using a logit 
transformation:66 ln  . 
Analytic Approach for Each Hypothesis 
Statistical tests were two-tailed with a critical alpha of .05. Models involving school 
entry requirements for Tdap controlled for the presence of requirements for meningococcal 
vaccine (n=16 states in 2012) and HPV vaccine (n=2 states in 2012). For analyses using 
structural equation modeling (SEM), I evaluated model fit using standard indices,67 including 
the root mean square error of approximation (RMSEA), which should be ≤ 0.05 with an 
upper confidence interval that does not include 0.08. If the data did not fit the models 
adequately, I searched for modifications to improve model fit according to standard 
guidelines,67 and if adequate fit was still not achieved, I fit path models using ordinary least 
squares regression. SEM models employed maximum likelihood estimation with robust 
standard errors that accounted for repeated measurement across years. I implemented SEM 
analyses in Mplus v7; all other analyses used SAS version 9.3. Analyses incorporated survey 
weights provided by NIS-Teen to account for non-equal probability of selection. 
Hypothesis 1a tested whether Tdap and HPV vaccine coverage is higher in states with 
Tdap school entry requirements than in states without such requirements. I tested this 
relationship for study years 2008 to 2012 (Figure 4). I used longitudinal SEM to examine the 
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association between having a Tdap school entry requirement in a given year and Tdap and 
HPV vaccine coverage in the following year (i.e., lag of one year). If this hypothesis were 
supported, I expected that the coefficients for the paths from school entry requirements to 
vaccine coverage would be statistically significant (diagonal arrows in Figure 4), controlling 
for contemporaneous and prior measures of vaccine coverage. In addition, I tested the 
invariance of these coefficients over the study period; I expected that the magnitude of this 
relationship will be invariant over time.  
Hypothesis 1b was an exploratory test of the effect of state HPV vaccine school entry 
requirements on state coverage with HPV vaccine. The analytic approach for this hypothesis 
followed the approach used for Hypothesis 1a, except that the independent variable was state 
HPV vaccine school entry requirements instead of requirements for Tdap. I viewed these 
analyses as exploratory given that only two jurisdictions (i.e., Virginia and Washington, 
D.C.) have instituted the policies, albeit they have been in effect for several years.37 
For Hypothesis 1c, I used Edwards’s method of cyclical analysis68 to examine the 
significance and magnitude of annual cyclical effects in Tdap, HPV, and concomitant 
vaccination for each state and for the United States overall. Edwards’s method is the most 
commonly used strategy for testing seasonal effects.53,56,58,59 Edwards’s method tests how far 
the data differ from a pattern of non-seasonality (i.e., flat rate or no peak) by fitting a 
harmonic sine curve with one peak and one trough per year to the observed data.  
First, Edwards’s method establishes whether a statistically significant cyclical effect 
exists in the observed data. Edwards’s T is defined as: 
 =  	8 Σ
   ×  Σ   sin  +  Σ    cos 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where i is the month, Ni is equal to the number of adolescents vaccinated in month i, 
and θi is equal to (2i – 1)*(π/12). Edwards’s T statistic has a χ2 distribution with 2 degrees of 
freedom.  
Second, Edwards’s method establishes the magnitude of the observed peak, i.e., the 
size of the cyclical effect. It uses as a metric, d, defined as: 
 =  Σ
   sin  +  Σ    cos  
 Σ    
A more intuitive measure of the magnitude of the peak is the ratio of the highest to 
the lowest (RHL) incidence. I used this measure to summarize peaks in vaccination. RHL 
and its variance are defined as: 
 !" =  1 + 41 − 4    ;     '()* !"+ =
2
      
In addition, Edwards’s method also offers an equation to calculate the maximum 
point on the fitted sine curve, i.e., the time when vaccination peaks.  
-./ =  tan 2 Σ
   sin 
Σ    cos 3 
To test whether cyclical effects exist, I compared Edwards’s T statistic to the critical 
value for a χ2 distribution with 2 degrees of freedom at p <.05 (i.e., 5.99) separately for each 
state and the United States, for each year and averaged across the study period. T statistics 
that exceeded that value indicated that the RHL for each adolescent vaccination cycle was 
significantly greater than 1. Finally, I verified that the peak of the vaccination occurs during 
the summer months (i.e., July, August, or September) using the θmax calculation coupled with 
visual inspection. I described an overall period that contained the national peak and at least 
50% of states’ peaks to highlight a few months in which adolescent vaccination was most 
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common. Months of maximum vaccination may have differed for the three outcomes, but I 
expected that they would all be in the summer. 
Finally, for Hypothesis 1d, I examined whether cyclical effects in concomitant 
vaccination (summarized by RHL) mediated the relationship between Tdap school entry 
requirements and state HPV vaccine coverage using longitudinal SEM (Figure 5).67 This 
approach allowed me to inspect the temporal relationships among the study variables by 
examining the lagged effects of Tdap requirements on concomitant vaccination and HPV 
vaccine coverage (paths from Tdap requirements to HPV vaccine coverage in the following 
year are excluded from Figure 5 for simplicity). If Hypothesis 1d was supported, the 
coefficients for the indirect effects of Tdap school requirements to peaks in vaccination to 
HPV vaccine coverage would be statistically significant. That is, controlling for state cycles 
of concomitant vaccination would result in a statistically significant reduction in the strength 
of the relationship between state Tdap school entry requirements and state HPV vaccine 
coverage. I tested the invariance of this indirect effect over the five years in the study period; 
I expected that the magnitude of this effect would be invariant over time. In addition, I 
expected the cross-sectional relationships between (1) Tdap school entry requirements and 
cyclical effects in concomitant vaccination, (2) Tdap school entry requirements and state 
HPV vaccine coverage, and (3) cyclical effects in concomitant vaccination and state HPV 
vaccine coverage to be statistically significant. 
Power Analysis 
The longitudinal SEM analysis for Hypothesis 1d examined 255 observations (51 
states with 5 observations each). The intra-class correlation for states’ HPV vaccine coverage 
from 2008 to 2012 is equal to 0.40, for a design effect of 2.6. Applying this design effect to 
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the power analysis calculations accounts for clustering within states. Across the study period, 
a median of 32 states had Tdap requirements and 19 states did not. The median level of HPV 
vaccine initiation between 2008 and 2012 was 49.4% (logit-transformed=-0.024). With a 
critical alpha of .05 and a beta of .80, the main analysis had the power to detect a mean 
difference of 4% in HPV vaccine coverage between states with and without Tdap 
requirements. 
Implications of Cyclical Effects in Adolescent Vaccination 
Documenting and analyzing cyclical effects in adolescent vaccination is important for 
understanding and improving the context in which adolescent vaccination takes place. 
Recognizing these peaks can help identify times during which programs promoting 
adolescent vaccines could be most effective and efficient. Just as retailers focus their 
marketing efforts during times of peak consumption (e.g., Christmas), so could public health 
focus its limited resources on adolescent vaccine promotion campaigns during regular 
vaccination peaks. For instance, agencies promoting adolescent vaccination may implement 
educational or social media campaigns in the late spring or summer months to encourage 
parents to have their children vaccinated. These interventions could exaggerate the already 
existing summer peaks, with overall greater numbers of adolescents protected with their 
recommended vaccines. Interventions that occur in fall or winter months may have less 
influence on rates of uptake because vaccination behaviors dwindle during that period. To 
our knowledge, interventionists do not currently consider the role of annual cycles in 
vaccination on the potential outcomes of their promotional programs. 
In addition, cyclical effects in adolescent vaccination could explain the relationship 
between Tdap school entry requirements and rates of uptake of a non-targeted vaccine, i.e., 
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HPV vaccine. Given that implementing HPV vaccine school entry requirements is currently 
politically infeasible, this finding could demonstrate that, in the context of Tdap 
requirements, promoting concomitant vaccination (especially during summer months) could 
advance efforts to increase HPV vaccine coverage. 
 
Figure 2. Average number of adolescent vaccine doses administered per month, 2008–2012, 
North Carolina. 
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Figure 3. Conceptual model of the effects of cycles in adolescent vaccination on the 
relationship between school entry requirements and state vaccine coverage (Aim 1). 
 
 
 
 
Figure 4. Path analytic model for longitudinal effects of Tdap school entry requirements on 
state vaccine coverage with Tdap and HPV vaccine, Hypothesis 1.a. 
 
 
  
27 
Figure 5. Path analytic model for longitudinal mediation of state cycles of concomitant 
vaccination of the relationship between state Tdap school entry requirements and state HPV 
vaccine coverage, Hypothesis 1.d. 
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CHAPTER 4: PATIENT-PROVIDER COMMUNICATION ABOUT  
VACCINES 
Aim 2 of the dissertation addresses the association between patient-provider 
communication and uptake of HPV vaccine. It also addresses how this relationship may vary 
depending on vaccine school entry requirements. In this chapter, I summarize the research 
literature on patient-provider communication and its relationship to vaccination, present the 
conceptual model and hypotheses for this aim, describe the proposed analytic methods, and 
discuss implications of this research. 
Patient-Provider Communication and Vaccination Decisions 
Parents are the primary decision makers regarding vaccinations for adolescents.69-71 
In the United States, parental vaccine hesitancy or opposition is becoming more common. 
Although Gust and colleagues72 reported in 2005 that less than 3% of parents in the United 
States were seriously opposed to vaccination, three more recent studies found that at least 
15% of parents had actively refused a vaccine during a healthcare encounter.45,73,74 Rates of 
vaccine refusal are increasing,33,46,74 and outbreaks of vaccine-preventable diseases have 
resulted.33,75-77 Parental vaccine refusal is becoming a serious threat to public health in the 
United States, but healthcare providers may be able to intervene to increase vaccination 
rates.77 
Parents often solicit the advice of healthcare providers before having their children 
vaccinated,33,34,70,73,78 and regardless of parents’ own personal opinions, most accept 
vaccination of their children.34,45,46,71-73,79-83 During a healthcare visit, a provider can educate 
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a vaccine-hesitant parent on vaccine safety and the potential harms of refusing to vaccinate, 
helping the parent consent to vaccinatation.45,73,84 For example, Freed and colleagues45 
surveyed a national sample of parents and found that half reported concerns about serious 
side effects of vaccines and 25% believed that vaccines cause autism. However, almost 90% 
of these parents reported following their doctors’ recommendations regarding vaccines for 
their children.45  
Indeed, a recommendation from a physician is one of the strongest and most 
consistent predictors of uptake of HPV vaccine.70,71,85-92 However, many healthcare providers 
report being uncertain how to offer such a recommendation.69,93-96 Some providers are not 
knowledgeable enough about HPV and HPV vaccine to offer an appropriate response if 
parents ask for specific information.71,95 Many providers indicate that they anticipate 
resistance from parents toward vaccines69,94,97 or anticipate that the cost of HPV vaccine may 
be too burdensome to some families.95,97 Among providers who recommend HPV vaccine, a 
subset selectively offer the vaccine only to older adolescents or those they believe to be at 
risk for acquiring HPV.69,71,94,96  
Many researchers and clinicians have concluded that primary healthcare providers 
need more training on how to offer HPV vaccine recommendations.28,33,45,69,70,74,80,84,85,94-96,98 
However, less agreement exists regarding the style with which providers should offer 
recommendations. In the past few decades, primary healthcare has moved toward a more 
collaborative, rather than directive, model of decision making.99 Collaborative decision 
making simultaneously respects the patient’s autonomy and values the provider’s healthcare 
training, and such models often emphasize the importance of rapport, dialogue, and 
emotional communication.99-104 Compared to more directive models of decision making, 
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collaborative approaches are associated with improved parental satisfaction with the 
healthcare encounter103 and healthcare decisions,105 reduced parental concerns about safety of 
a medical intervention,102 increased adherence to medical recommendations,103,106 and 
improved clinical outcomes.103 For example, Murray, Charles, and Gafni101 presented a 
model for communication between providers and patients in the context of primary 
healthcare that emphasized information exchange, deliberation, and decision making; the 
authors suggested that when all three of these processes occur collaboratively, patients 
engage in the optimal health-related behavior.  
However, medical ethics generally deems collaborative decision making unnecessary 
in situations in which there is only one medically acceptable choice, as is the case with 
vaccines.107 In these latter situations, it is the provider’s responsibility to guide the patient 
toward the healthful decision and not encourage the patient to make an alternative choice to 
avoid putting the patient at undue risk.107 In the context of adolescent vaccines, collaborative 
decision making may put patients at risk by encouraging parents to opt out of vaccination. 
Recent research findings support this conclusion.69,108  
Opel and colleagues108 evaluated provider communication practices when discussing 
vaccines in 111 videotaped healthcare encounters with patients and parents. The authors 
classified patient-provider communication as presumptive (i.e., non-collaborative) when 
providers presupposed that the parent would accept vaccines, e.g., by giving declarations that 
the provider would give the child shots that day. For conversations that did not presuppose 
that parents would accept vaccines, e.g., because providers gave parents latitude to refuse 
vaccines by asking questions, the authors classified communication as participatory (i.e., 
collaborative). They found that 74% of providers used a presumptive approach and 26% used 
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a participatory approach. In response to presumptive patient-provider communication, 74% 
of parents accepted vaccination, but only 4% of parents accepted vaccination when providers 
used a participatory approach (odds ratio adjusted for parental vaccine hesitancy = 17.5, 95% 
confidence interval = 1.2, 253.5).108 In that study, collaborative patient-provider 
communication hindered parent acceptance of vaccines for their children, potentially 
endangering their children’s health. 
Non-collaborative patient-provider communication can result in higher levels of 
vaccine uptake by framing vaccination as the default choice.48,49 Consider again the three 
explanations for the default effect: interpreting the default choice as a suggestion from health 
authorities, less effort required to engage in the default choice, and loss aversion when 
evaluating an alternative in reference to the default choice. The effort involved in accepting 
versus refusing a vaccine once a patient is already at the healthcare provider’s office is fairly 
equivalent, so communication style probably does not influence a parent’s perceptions about 
how effortful a given behavior is. However, the suggestion and loss aversion explanations are 
likely to be relevant for the relationship between patient-provider communication and 
vaccination behaviors. Providers who use a presumptive approach during vaccine discussions 
offer implicit (or even explicit) endorsements of vaccination, while providers who use a 
collaborative approach may appear less enthusiastic about vaccination or may imply that 
uncertainty exists about the vaccine. In addition, when providers use a presumptive 
communication style, parents must evaluate the potential losses of vaccine refusal in 
reference to the default of vaccine acceptance. In contrast, when providers use a collaborative 
communication style, parents may perceive that there is no default behavior or that vaccine 
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refusal is the default, and therefore loss aversion may not tip their decision making process in 
favor of vaccine acceptance.  
In sum, though collaborative patient-provider communication is associated with 
healthful decision making in many healthcare contexts, collaborative discussions about 
vaccines may actually be associated with lower uptake. Ethically, presumptive 
communication may be more appropriate than collaborative communication given that 
medically appropriate alternatives to vaccination do not exist. In addition, presumptive 
communication may frame vaccine acceptance as a default choice, which can optimize 
vaccination behaviors. Overall, the effect of communication style on receipt of adolescent 
vaccines remains unclear. 
Studies have not yet investigated whether school entry requirements might moderate 
the association of providers’ communication style with uptake of adolescent vaccines. In 
states without school entry requirements, communication style may be particularly influential 
for parents’ decisions. Because policymakers in those states do not endorse vaccination, 
providers’ expectations about vaccination, conveyed through their communication style, may 
become even more important in affecting vaccine uptake. In contrast, parents in states with 
school entry requirements may be motivated to seek vaccinations regardless of physician 
communication style to comply with the vaccine policy. However, many states have policies 
that require adolescents to receive Tdap but do not require HPV vaccine. In these contexts, 
communication style may become more important for acceptance of HPV vaccine because 
providers must compensate for policymakers’ failure to frame HPV vaccination as the default 
choice. 
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In conclusion, healthcare providers’ advice strongly influences parents’ decisions to 
vaccinate their children. Although some parents have doubts about whether or not to 
vaccinate and vaccine refusals are becoming more common, most parents follow the advice 
of their providers. Specifically for HPV vaccine, providers need more education on how to 
offer effective recommendations. Although style of communication is likely important for 
decision making around adolescent vaccines, genuine uncertainty exists around whether a 
collaborative or non-collaborative approach is preferable for increasing uptake. It is plausible 
that provider recommendation interacts with the policy environment around adolescent 
vaccines, but more research is needed. 
Conceptual Model and Hypotheses 
The conceptual model in Figure 6 depicts the relationships under study in Aim 2. In 
brief, this aim examined (1) how three aspects of collaborative patient-provider 
communication correlated with uptake of HPV vaccine, and (2) how these relationships 
varied across states with and without school entry requirements for Tdap vaccine.  
In Aim 2, I studied three aspects of collaborative patient-provider communication 
(i.e., information exchange, deliberation, decision), as well as uptake of adolescent vaccines 
and state vaccine school entry requirements. Following Charles and colleagues’100,101 
description of collaborative patient-provider communication, information exchange indicated 
whether providers talked with parents about a given vaccine. Deliberation captured whether 
providers gave parents time to discuss and think about whether or not to have a child 
vaccinated. Decision reflected whether providers played a role in the parents’ decision 
making process. Uptake of adolescent vaccines was a measure of an individual’s receipt of 
Tdap and HPV vaccines, as well as receipt of both vaccines concomitantly. Finally, per the 
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description of this construct above, state Tdap school entry requirements indicated whether a 
state had a policy in effect requiring that adolescents receive Tdap vaccine prior to school 
entry. Note that I examined the relationship between state school entry requirements and 
vaccination behaviors as part of Aim 1 (Hypotheses 1a and 1b). I describe more fully the 
proposed relationships among the variables in Aim 2 in the hypotheses below. Due to the 
genuine uncertainty regarding the relationship between collaborative patient-provider 
communication and uptake of adolescent vaccines, particularly HPV vaccine, I present two 
competing hypotheses about the main effects of dimensions of collaborative communication, 
as well a moderating hypothesis. 
 
Hypothesis 2a. Collaborative patient-provider communication will be positively 
associated with adolescents’ receipt of Tdap and HPV vaccines. 
Collaborative patient-provider communication is associated with several positive 
healthcare outcomes.102-106 Charles and colleagues100,101 propose that patients make optimal 
healthcare decisions when providers use a collaborative communication style. Per these 
empirical and theoretical findings, I hypothesized that collaborative patient-provider 
communication would be positively associated with uptake of adolescent vaccines. 
 
Hypothesis 2b. Collaborative patient-provider communication will be negatively 
associated with adolescents’ receipt of Tdap and HPV vaccines. 
Collaborative patient-provider communication is often unnecessary for decisions 
about vaccines, given that there is no medically acceptable alternative.107 Non-collaborative 
communication styles frame adolescent vaccination as a default choice,48,49 and empirical 
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studies find that parents are more likely to accept vaccines when providers use a non-
collaborative approach.108 Thus, I hypothesized that collaborative patient-provider 
communication would be negatively associated with uptake of adolescent vaccines. 
 
Hypothesis 2c. Collaborative patient-provider communication and state Tdap school 
entry requirements will interact in their association with uptake of HPV vaccine and 
concomitant vaccination such that the relationship between collaborative communication 
and vaccination will be stronger in states with Tdap school entry requirements than in states 
without Tdap school entry requirements. 
Most states with Tdap school entry requirements do not have comparable policies 
requiring HPV vaccination. In those contexts, parents may perceive policymakers’ implicit 
endorsement of Tdap and rejection of HPV vaccine. Therefore, provider communication 
style becomes even more important in a parent’s decision-making process, particularly in 
regards to whether or not a provider endorses of the vaccine. A collaborative communication 
style about HPV vaccination does not convey the provider’s endorsement of the vaccine, 
while a non-collaborative style does convey an endorsement. For parents living in states 
without Tdap school entry requirements, parents do not have to compensate for 
policymakers’ implicit rejection of HPV vaccine as they decide whether to vaccinate, and 
provider communication style may be less influential for HPV vaccine uptake.  
In addition, the relationship described previously will have a smaller carry-over effect 
on concomitant vaccination, so I anticipated that analysis of this outcome would demonstrate 
a comparable pattern of results.  
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However, I did not expect that Tdap school entry requirements would moderate the 
relationship between collaborative patient-provider communication and uptake of Tdap 
vaccine. States that do not have Tdap school entry requirements do not require students to 
receive other adolescent vaccines, so providers’ communication styles in these states may be 
less influential in terms of compensating for policymakers’ implicit vaccine rejection in 
parental decision making.  
Proposed Analytical and Statistical Methods 
Data Sources 
As part of Aim 2, I analyzed data from two sources: National Immunization Survey-
Teen (NIS-Teen) and the Immunization Action Coalition (IAC).  
In two quarters of survey year 2010, NIS-Teen (described previously) included the 
Parental Attitudes Module.61 Measures of collaborative patient-provider communication for 
Aim 2 came from the second section of the Parental Attitudes Module, “Influences on 
parents’ decisions about vaccines.” Information on uptake of HPV vaccine came from NIS-
Teen records for participants who completed the Parental Attitudes Module. 
As described previously, the IAC compiles data from state health departments on 
school entry requirements for vaccination, including whether each state has a Tdap 
requirement, and, if so, when it became effective.37 
Measures 
The conceptual model for Aim 2 (Figure 6) includes five constructs: information 
exchange, deliberation, decision, uptake of adolescent vaccines, and state Tdap school entry 
requirements. I analyzed these items only among the subsample of parents who answered 
questions about female adolescents. This analysis was limited to respondents from two 
37 
quarters of the 2010 survey year, when NIS-Teen implemented the Parental Attitudes 
Module. 
I measured information exchange with one item: “At visits made for [teen name]’s 
vaccinations, did his/her healthcare provider talk to you about HPV shot?” Parents could 
respond yes or no to this item, or interviewers could select don’t know or refused if 
appropriate. I created a dichotomous measure of information exchange by assigning a value 
of 1 (for collaborative information exchange) for parents who responded yes and a value of 0 
(for non-collaborative information exchange) for parents who responded no, don’t know, or 
refused. 
I measured deliberation with one item: “At visits made for [teen name]’s 
vaccinations, did his/her healthcare provider give you enough time to discuss the HPV shot?” 
Again, parents could respond yes or no to these items. I created a dichotomous measure of 
deliberation by assigning a value of 1 (for collaborative deliberation) for parents who 
responded yes and a value of 0 (for non-collaborative deliberation) for parents who 
responded no, don’t know, or refused. 
I measured decision with one item: “At visits made for [teen name]’s vaccinations, 
did his/her healthcare provider play a role in your decision to get [teen name] vaccinated or 
not to get [teen name] vaccinated with the HPV shot?” Again, parents could respond yes or 
no to these items. I created a dichotomous measure of decision by assigning a value of 1 (for 
collaborative decision) for parents who responded yes and a value of 0 (for non-collaborative 
decision) for parents who responded no, don’t know, or refused. 
Adolescent vaccine uptake came from provider-verified reports of whether or not an 
adolescent had received at least one dose of HPV vaccine before completing the survey. 
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Finally, I measured whether or not a state had a Tdap school entry requirement in 
effect by Fall 2010 using a dichotomous indicator variable.  
Analytic Approach for Each Hypothesis 
Statistical tests were two-tailed with a critical alpha of .05. Models involving school 
entry requirements controlled for the presence of requirements for meningococcal vaccine 
(n=11 states in 2010) and HPV vaccine (n=2 states in 2010). All analyses used SAS version 
9.3. Analyses incorporated survey weights provided by NIS-Teen to account for non-equal 
probability of selection. 
To test Hypotheses 2a and 2b, I used bivariate and multivariate logistic regression to 
examine the effect of collaborative patient-provider communication on uptake of adolescent 
vaccines. I tested the effects of three dimensions of collaborative communication individually 
(i.e., in bivariate regression), and then I built a model including all of the dimensions of 
collaborative communication that demonstrated statistically significant relationships with 
uptake of adolescent vaccines in bivariate models. If Hypothesis 2a were supported, the beta 
coefficients for the communication variables would be statistically significant and positive, 
but if Hypothesis 2b were supported, the beta coefficient would be statistically significant 
and negative.  
Hypothesis 2c involved examining the moderating effect of Tdap school entry 
requirements on the relationship between collaborative communication and uptake of 
adolescent vaccines. I conducted additional logistic regression analyses, adding interaction 
terms for the dimensions of collaborative communication with presence of a Tdap school 
entry requirement. If Hypothesis 2c were supported, then the interaction terms for the 
relationship of Tdap requirements and dimensions of collaborative communication on HPV 
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and concomitant vaccination would be statistically significant. I did not expect the interaction 
terms for the relationship of Tdap requirements and dimensions of collaborative 
communication on Tdap vaccination to be statistically significant. In addition, post-hoc tests 
would reveal that the association between the communication variables and adolescent 
vaccination were stronger for states with Tdap requirements than for states without Tdap 
requirements. 
Power Analysis 
Parents of 4,610 adolescent females completed the NIS-Teen Parental Attitudes 
Module and have provider-verified data on HPV vaccine uptake. Opel and colleagues108 
estimated that the proportion of providers using a collaborative communication style was 
26% and the proportion using a non-collaborative style was 74%. In 2010, 49% of all 
adolescent females had received at least one dose of HPV vaccine. With a critical alpha of 
.05 and a beta of .80, the analysis in Hypotheses 2a and 2b had the power to detect a mean 
difference of <5% in HPV vaccine coverage between adolescents whose providers used a 
collaborative versus a non-collaborative communication style.  
Implications of the Effect of Patient-Provider Communication on Adolescent 
Vaccination 
Parsing out the effects of collaborative patient-provider communication on uptake of 
adolescent vaccines has consequences for provider training in how to encourage adolescent 
vaccination. Although provider recommendation is one of the strongest and most consistent 
correlates of vaccination, little is known about how style of communication influences 
vaccine uptake. Ethics, theory, and empirical findings on patient-provider communication 
about childhood vaccines provide contradictory suggestions about whether this relationship 
could be positive or negative. The findings from this aim could inform educational 
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interventions that teach providers how to discuss adolescent vaccines, especially HPV 
vaccine, with patients and their parents. In addition, understanding how the health policy 
context moderates the association between patient-provider communication and adolescent 
vaccination will deepen the scientific understanding of how policies shape behaviors.  
 
Figure 6. Conceptual model of the relationships among collaborative patient-provider 
communication, state vaccine school entry requirements, and uptake of adolescent vaccines. 
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CHAPTER 5: YEARLY CYCLES IN ADOLESCENT VACCINATION,  
UNITED STATES 
Introduction 
National guidelines recommend that 11- and 12-year olds routinely receive three 
adolescent vaccines: tetanus, diphtheria, and pertussis (Tdap) booster, meningococcal 
vaccine, and a three-dose series of human papillomavirus (HPV) vaccine.15 Healthy People 
2020 set the goal for 80% of 13- to 15-year-old adolescents to receive each of these 
vaccines,27 and though coverage for Tdap booster has surpassed that level and 
meningococcal vaccine is quickly approaching it, coverage for HPV vaccine falls far short. 
Only 28% of females and 7% of males in this age group have received the entire HPV 
vaccine series as of 2012.5,27 Failing to meet these goals could have a tremendous impact on 
population health; achieving 80% coverage with HPV vaccination could prevent an 
additional 53,000 cases of cervical cancer over the lifetime of females who are now age 12 or 
younger.109 For this reason, the Centers for Disease Control and Prevention (CDC), the 
National Cancer Institute, and other national organizations have prioritized increasing HPV 
vaccination.27,110,111  
In some locations in the United States, adolescent vaccination appears to demonstrate 
a cyclical pattern, with increased numbers of adolescents receiving vaccines during the 
summer months compared to the rest of the year.112,113 However, whether this is a national 
phenomenon is unknown and previous demonstrations of cyclical patterns have mostly 
employed descriptive rather than inferential methods. Several factors could give rise to this 
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pattern, including parents seeking to comply with vaccine school entry requirements37 before 
the school year begins, requirements for summer camps, the relative ease of pursuing 
preventive healthcare when most students are on summer break, and the tendency to schedule 
well-child visits around the time of a child’s birthday (which is slightly more likely to occur 
in the summer compared to winter months114). Understanding cyclical variation in adolescent 
vaccination has implications for healthcare practice and public health in terms of timing 
quality improvement or promotional programs, an especially important consideration for 
HPV vaccination. Our study sought to evaluate patterns in adolescent vaccination in the 
United States using several years of population-based clinical data. 
Patients and Methods 
Data Source 
Data came from the 2008–2012 versions of the National Immunization Survey (NIS)-
Teen conducted by the CDC.61 NIS-Teen is a two-part survey consisting of telephone 
interviews administered to a national probability sample of caregivers of 13- to 17-year-old 
adolescents (hereafter referred to as “parents”) and questionnaires mailed to the adolescents’ 
primary healthcare providers.  
NIS-Teen employed list-assisted random-digit dialing methods to compile telephone 
numbers for a sample of potential participants. Using a national database of residential 
telephone numbers, NIS-Teen staff then sent advance letters to addresses that were linked to 
the sample telephone numbers, alerting the household to the upcoming phone contact. In 
2008–2010, NIS-Teen staff contacted parents through landline numbers, and in 20112012, 
staff also contacted parents through cell phone numbers.  
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At the end of the telephone interviews, interviewers asked participating parents for 
consent to contact the pediatricians, family practitioners, or other clinical providers who may 
have medical records containing adolescents’ vaccination history. Parents provided contact 
information for these providers, allowing NIS-Teen staff to mail two-page written 
questionnaires to providers’ offices. If providers did not return questionnaires within 2 
weeks, NIS-Teen staff called providers to encourage them to complete and return them. 
Between 2008 and 2012, NIS-Teen collected provider-verified vaccination data for 
about 20,000 adolescents living in the 50 states and Washington D.C. (hereafter referred to 
collectively as “states” for the sake of simplicity) each year, for a cumulative total of 101,517 
adolescents.61 Because we were interested in dates of adolescent vaccination, which is 
conditional on actually receiving at least 1 vaccine, we excluded participants who had no 
provider-verified vaccination (n=19,932). In addition, we excluded participants who had 
received at least 1 vaccine but their provider either reported that all dates of administration 
fell outside of the study period (n=8,642) or did not report the dates of administration (n=12), 
for a final analytic sample of 72,931 adolescents. NIS-Teen staff calculated sampling weights 
for each participant with provider-verified data to account for non-equal probability of 
selection. 
Data collection for NIS-Teen was approved by the National Center for Health 
Statistics (NCHS) Research Ethics Review Board. Analysis of de-identified data from the 
survey is exempt from the federal regulations for the protection of human research 
participants. Analysis of restricted data through the NCHS Research Data Center is also 
approved by the NCHS Ethics Review Board. The University of North Carolina Institutional 
Review Board exempted our study from review.  
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Measures 
On the mailed questionnaires, healthcare providers reported whether adolescents 
received Tdap booster, meningococcal vaccine, and HPV vaccine and, if so, the month, date, 
and year of administration. Although data collection took place beginning in 2008, we 
included instances of vaccination that occurred on or after January 1, 2007, in this analysis 
because providers could report any vaccine administration that took place before (and up to 
the date of) the NIS-Teen phone interviews. We used data for HPV vaccine initiation (i.e., 
receipt of the first dose of the three-dose series) only among female adolescents because the 
CDC did not introduce a recommendation for routine administration to male adolescents until 
2011.4 We coded participants as receiving vaccines concomitantly if providers reported 
administration of the vaccines on the same day.31 Thus, we captured whether adolescents 
concomitantly received 4 possible combinations of vaccines: (1) Tdap booster and 
meningococcal vaccine; (2) Tdap booster and HPV vaccine; (3) meningococcal and HPV 
vaccines; and (4) Tdap booster, meningococcal vaccine, and HPV vaccine. State of residence 
and demographic characteristics came from parental report in the NIS-Teen telephone 
survey.  
Data Analysis 
Data preparation. We combined data from the 2008 to 2012 versions of NIS-Teen 
using NCHS’s recommended procedures that include creating new weighting variables.61 
Then we categorized participants according to the month and year in which they received 
vaccines and generated weighted estimates of the total number of vaccine doses administered 
in each month of the study period. We standardized the length of each month by dividing the 
monthly vaccination totals by the number of days in the month and multiplying by 30, so that 
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each month contributed equally to the yearly cycles. This approach may be unnecessary 
when analyzing large samples,68 but some researchers have noted the value of using this 
standardization technique to remove the influence of month length from studies of 
seasonality.56,115 For analyses that combined vaccination data from multiple years, we 
weighted each year’s observations so that years contributed equally to the combined cycles. 
To create figures depicting vaccination peaks for individual states and for the United 
States, we put the number of people receiving a vaccine in a given month on a common 
metric, following recommendations by Rau.56,116 To do so, we calculated the number of 
people who received the vaccine each month, and then rescaled the data so that the yearly 
total was 1,200. Any month with a scaled vaccination total exceeding 100 contained greater 
vaccination than would be expected if vaccination were randomly distributed over time, and 
any month with a scaled vaccination total of less than 100 contained less vaccination than 
expected. This approach facilitates descriptive comparison of cyclical patterns between units 
of geography with different population sizes. Note that the inferential procedures described 
next did not use these scaled observations but instead analyzed month- and year-standardized 
data (described previously). 
Inferential analysis. For all data years combined, we examined cyclical patterns for 
the United States overall and within each state, and then within each study year for the 
United States. These three approaches allowed us to check for consistency of cyclical 
patterns across geography and time. We performed these calculations separately for the Tdap 
booster, meningococcal vaccine, and HPV vaccine, as well as for each of the four possible 
concomitant vaccination outcomes. Small sample sizes precluded generating estimates for 
each study year separately within states; for concomitant vaccination within states; and for 
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2012, the final study year, separately from the preceding years (i.e., because vaccination that 
occurred in 2012 could only be reported by participants in the 2012 survey).   
To test the statistical significance of cyclical patterns, we used Edwards’s method,56,68 
the most commonly used analytic approach in seasonality research.56 Briefly, the Edwards 
method involves fitting a harmonic sine curve with one peak and one trough to the observed 
data in each month. (Before implementing these methods, we verified with visual inspection 
that the data did not follow a qualitatively different form, e.g., bimodal, which would require 
different analytic tools.) Edwards’s T statistic, which measures how far the fitted curve 
differs from non-seasonality (i.e., a flat line), follows a chi-square distribution with 2 degrees 
of freedom. The ratio of highest to lowest (RHL) incidence examines the amplitude of the 
fitted curve to describe the relative increase in the outcome at the cycle’s maximum (i.e., its 
peak) compared to its minimum (i.e., its trough).56,68 Previous studies in public health have 
used Edwards’s method to assess cyclical patterns in outcomes such as cardiovascular 
disease, suicide, and malaria.53,58,59 For each vaccination outcome in the current study, we 
fitted a sine curve to the observed vaccination data and calculated the resulting T statistic. In 
addition, we examined the RHL to summarize the magnitude of the cyclical pattern in 
vaccination.  
All analyses were conducted in SAS version 9.2 (Cary, NC). Statistical tests used a 
two-tailed p value of .05. Analyses incorporated survey weights to account for non-equal 
probability of selection.  
Results 
The 72,931 vaccinated adolescents were nearly evenly distributed by sex and age 
(Table 1). Most adolescents were non-Hispanic white (57.2%), had private health insurance 
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(60.7%), and had a preventive healthcare visit in the past year (87.1%). The majority of 
adolescents lived in metropolitan households (86.8%) above the poverty level (74.3%). 
Uptake of Single Adolescent Vaccines 
Adolescent vaccination in the United States increased in late spring, crested in 
August, and decreased rapidly thereafter (black lines in Figure 7). For 2007–2012 combined, 
uptake was highest in the months of June, July, and August; healthcare providers 
administered about 40% of all vaccine doses during this period (Tdap booster: 40.2%; 
meningococcal vaccine: 41.1%; HPV vaccine: 38.7%) (Table 2). Each vaccination outcome 
demonstrated cyclical patterns (all p<.001) (Table 3). For Tdap booster, the RHL was 5.1, 
indicating that vaccination was 5 times as frequent at the cycle’s peak as at its trough. The 
RHL was 10.1 for meningococcal vaccine and 4.7 for HPV vaccine. 
Adolescent vaccination in individual states largely demonstrated the same summer 
peaks as in the United States overall (gray lines in Figure 7). For each state, each vaccination 
outcome demonstrated cyclical patterns (all p<.001) (Supplementary Table S1). The RHLs of 
states’ cycles varied from 3.0 in Washington, D.C., to 13.3 in Utah for Tdap booster; from 
4.9 in Arizona to 40.3 in Nevada for meningococcal vaccine; and from 2.5 in New Mexico to 
98.2 in Nevada for HPV vaccine.  
The pattern of increased vaccination in the summer was also present when examined 
within each individual year (Figure 8). For each year, each vaccination outcome 
demonstrated cyclical patterns (all p<.001) (Table 3). Over time, the RHLs of the cycles for 
Tdap booster increased slightly, from 4.5 in 2008 to 6.6 in 2011. For meningococcal vaccine, 
the RHLs increased dramatically, from 7.5 in 2007 to 21.2 in 2011. However, for HPV 
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vaccine, the RHLs varied from year to year with no clear pattern, ranging from 4.5 in 2008 to 
5.7 in 2010.  
Concomitant Uptake of Adolescent Vaccines 
Concomitant vaccination showed a pattern similar to the findings for individual 
vaccines, increasing in late spring, cresting in the summer months, and decreasing rapidly 
thereafter (Supplementary Figure S1). Concomitant adolescent vaccination was highest in the 
months of June, July, and August; about 40% of all concomitant vaccination took place 
during this period (Table 2). Each concomitant adolescent vaccination outcome demonstrated 
cyclical patterns for the United States both across and within study years (all p<.001) (Table 
4).  
Conclusion  
Across the United States, uptake of adolescent vaccines demonstrated consistent 
yearly cycles with peaks in the summer. From 2007 to 2012, healthcare providers 
administered around 40% of these vaccines during June, July, and August. Compared to 
vaccination at the trough of each cycle, vaccination at the peak was about 5 times as high for 
Tdap booster and HPV vaccine and about 10 times as high for meningococcal vaccine. The 
pattern of summer peaks in adolescent vaccination occurred across years and within each 
state.  For concomitant vaccination, the peaks were similar though somewhat smaller. 
Summer peaks in adolescent vaccine provision appear to be robust, but more research 
is needed to better understand what causes them. Vaccination requirements for school entry 
may encourage parents and adolescents to seek vaccination in the summer months.37 As of 
Fall 2014, 47 states had school entry requirements for Tdap and 20 states had requirements 
for meningococcal vaccination.37 In support of this hypothesis, we found that cycles of 
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adolescent vaccination generally reached their peaks in August, which coincides with the 
beginning of the school year in most areas of the United States. These policies could also 
explain some of the difference in magnitude of cyclical effects for Tdap booster versus 
meningococcal vaccine: generally, states with requirements for the latter vaccine adopted 
them more recently. Their more recent implementation may exaggerate the observed summer 
peaks as parents newly rush to comply. Additional research is needed on the possible 
connection between school entry requirements and summer peaks in adolescent vaccination. 
An alternative explanation is that seeking adolescent vaccination is easier when 
students are out of school. Were this the case, vaccination should have a secondary, albeit 
smaller, peak when schools close for winter break; however, we found that vaccination was 
actually least common in November and December. Any effect of adolescents being out of 
school during portions of those months may have been overwhelmed by the influence of 
families’ and healthcare clinics’ restricted schedules (due to travel, closures for the winter 
holidays, etc.). More research is needed on what motivates adolescents and parents to seek 
vaccination in the summer months. 
Our results extend the findings of two recent descriptive studies. Sull and 
colleagues112 used the New York City immunization information system (IIS) to measure 
monthly administration of Tdap booster, meningococcal vaccine, and HPV vaccine among 
11-year-old adolescents from 2005 to 2013. Starting in 2007, they found large increases in 
uptake of Tdap booster and meningococcal vaccine and small increases in uptake of HPV 
vaccine in the summer compared to the rest of the year. Cullen and colleagues113 used IIS 
data at 8 sentinel sites in the United States to analyze the weekly number of HPV vaccine 
doses administered among male and female adolescents aged 11–18 years. The authors 
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reported relative increases in HPV vaccination during the summers of 2010–2012. We 
expanded on these studies by using nationally representative data to quantify the magnitude 
of summer peaks across time and in each state, test their statistical significance, and examine 
cycles in concomitant vaccination. Taken together, these studies illustrate the presence of 
consistent cycles in the demand for adolescent vaccines, which has important implications 
for clinical practice and public health. 
Cyclical patterns in adolescent vaccination influence clinical practice for pediatric 
and family practice providers in at least three important ways. First, clinics should increase 
their supplies of adolescent vaccines during the summer and, potentially, reduce their 
supplies during the winter. Based on the observed data, clinics were able to serve more 
adolescents seeking vaccination in the summer, but we could not determine whether demand 
for vaccination exceeded availability of vaccine doses. Were this the case, summer peaks 
could be even larger in magnitude than we observed. Second, providers should consider 
implementing immunization quality improvement efforts during the spring months because 
the relative decrease in vaccination during those times affords more organizational capacity 
to make structural changes in preparation for summer increases in vaccination. Undertaking 
such programs during the summer would potentially be crowded out by the more immediate 
needs of serving adolescent patients. Third, summer peaks in uptake of single vaccines 
translate into increased opportunities for providers to recommend adolescent vaccines 
concomitantly. Given that a provider’s recommendation is the strongest and most consistent 
correlate of adolescent vaccination,6,70 recommending additional vaccines during 
immunization visits in the summer could bring about large increases in coverage for the 
entire adolescent vaccine platform. 
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In addition, these vaccination cycles have implications for public health practice and 
research. Promotion programs aimed at improving attitudes or intentions around adolescent 
vaccination may be especially fruitful if they occur in the late spring and early summer and 
can capitalize on the existing peaks. Similarly, interventions that happen during the summer 
peak may face reduced capacity among clinicians who are partners in evaluation. In addition, 
public health researchers need to account for these cyclical patterns when conducting 
evaluations to avoid misattributing secular increases in coverage in the summer to promotion 
or intervention activities. This issue of potential confounding is of greatest concern for 
uncontrolled research study designs.   
Study strengths include that we analyzed vaccination dates drawn from several years 
of a large, nationally representative survey.61 We used an objective measure of vaccination 
status (i.e., verified by healthcare providers). Our study employed a canonical analytic 
technique used in studies of seasonal phenomena across disciplines.56 In addition, our 
inclusion of concomitant vaccination is somewhat unique. Finally, we analyzed cycles of 
vaccination across three combinations of geography and time. Together, these strengths 
support the validity and reliability of our study conclusions. Study limitations include that we 
could not distinguish between adolescents’ current state of residence (the unit of analysis in 
this study) and the state in which they received their vaccines. Because the United States has 
high residential mobility,117 we can assume that some adolescents relocated during the time 
between vaccination and participation in NIS-Teen. For those adolescents, the state in which 
they received vaccines was likely misattributed. However, given the similarity of the 
vaccination cycles evident across states and across years, the effect of this misattribution is 
likely minimal. Another limitation is that although we were able to document and analyze 
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this cyclical phenomenon, we were unable to evaluate why and how it emerged. Future 
studies should examine parental motivations to vaccinate in the summer and their effects on 
the observed cycles 
In summary, we found marked summer peaks in uptake of adolescent vaccines from 
2007 to 2012. For the United States as a whole and for individual states, vaccination 
increased substantially during the summer months. Healthcare providers administered about 
40% of all adolescent vaccines during June, July, and August. These cycles have implications 
for both clinical practice (e.g., stocking up on adolescent vaccines during the summer) and 
public health (e.g., timing of vaccine promotion efforts). Future studies should evaluate how 
cyclical patterns emerge and how they affect population-level coverage with adolescent 
vaccines.  
Table 1. Descriptive Statistics of Participating Adolescents and Their Families (Source: 
National Immunization Survey-Teen) 
  Total Sample Male Female 
 n  (%)  n  (%)  n  (%) 
Total        72,931        35,862  48.2%   37,069  51.8% 
Survey year 
   2008          8,317  13.3%         3,256  11.9%     4,791  14.6% 
   2009        12,766  17.6%         5,943  16.8%     6,823  18.5% 
   2010        14,673  20.7%         7,237  21.0%     4,736  20.4% 
   2011        19,969  23.5%       10,156  24.3%     9,813  22.8% 
   2012        17,206  24.9%         9,000  26.1%     8,206  23.7% 
Child characteristics 
Age 
  13        15,822  21.0%         8,069  21.7%     7,753  20.3% 
  14        15,907  21.0%         8,046  21.6%     7,861  20.4% 
  15        15,183  21.9%         7,448  22.0%     7,735  21.9% 
  16        14,134  19.6%         6,784  19.2%     7,350  19.9% 
  17        11,885  16.5%         5,515  15.5%     6,370  17.5% 
Race/ethnicity 
   Hispanic          9,869  20.5%         4,832  20.6%     5,037  20.4% 
   Non-Hispanic white        49,577  57.2%       24,467  57.4%   25,110  57.0% 
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   Non-Hispanic black          7,355  14.3%         3,615  14.3%     3,740  14.4% 
   Other          6,130  8.0%         2,948  7.8%     3,182  8.2% 
Private health insurance 
   Yes        49,747  60.7%       24,351  60.0%   26,396  61.4% 
   No        22,796  39.3%       11,317  40.0%   26,396  38.7% 
Preventive visit in the 
last year 
   Yes        64,202  87.1%       31,466  86.5%   32,736  87.7% 
   No          8,729  12.9%         4,396  13.5%     4,333  12.3% 
Parent characteristics 
Relationship of 
respondent to teen 
   Mother/female 
guardian        58,030  76.8%       28,268  75.3%   29,762  78.3% 
   Father/male guardian        11,712  17.3%         6,022  18.7%     5,690  16.0% 
   Other          3,189  5.9%         1,572  6.0%     1,617  5.8% 
Education level 
   Less than high school          6,739  13.9%         3,276  14.0%     3,463  13.8% 
   High school        13,834  25.3%         6,895  25.7%     6,939  24.8% 
   Some post-high school        20,255  25.7%         9,858  25.0%   10,397  26.3% 
   College graduate        32,103  35.2%       15,833  35.3%   16,270  35.1% 
Household characteristics 
Poverty status 
   Below poverty level        10,291  20.7%         5,031  20.6%     5,260  20.8% 
   Above poverty level, 
≤$75,000        27,397  38.6%       13,562  39.2%   13,835  38.0% 
   Above poverty level, 
>$75,000        32,481  35.7%       15,885  35.2%   16,596  36.1% 
   Unknown          2,762  5.0%         1,384  5.0%     1,378  5.0% 
Urbanicity 
   Metropolitan        52,442  86.8%       25,746  86.1%   26,696  85.5% 
   Non-metropolitan        13,661  14.2%         6,577  13.9%     7,084  14.5% 
Census region 
   Northeast        15,850  19.4%         7,797  19.3%     8,053  19.6% 
   Midwest        16,217  21.6%         7,892  21.6%     8,325  21.5% 
   South        24,846  34.5%       12,256  34.6%   12,590  34.4% 
   West        16,018  24.6%         7,917  24.6%     8,101  24.5% 
 
Note. We present unweighted n’s and weighted percentages. 
 
 Table 2. Adolescent Vaccine Doses Administered Per Month in the United States  
  Single vaccination Concomitant vaccination 
 Tdap Meng HPV1 
Tdap and 
Meng 
Tdap and 
HPV1 
Meng and 
HPV1 All three 
n 55,269 53,200 22,849 26,999 6,520 8,894 4,371 
January 6.7% 6.2% 8.0% 6.3% 10.2% 7.1% 8.9% 
February 6.3% 7.2% 7.6% 6.0% 5.3% 7.2% 5.7% 
March 7.8% 7.6% 7.2% 8.2% 6.9% 7.8% 6.9% 
April 8.1% 7.8% 8.0% 8.4% 8.2% 8.9% 9.3% 
May 8.6% 7.4% 6.8% 8.2% 7.8% 7.2% 8.5% 
June 9.2% 10.0% 10.2% 9.1% 8.5% 8.5% 8.0% 
July 12.0% 13.1% 12.6% 12.9% 13.0% 12.8% 13.3% 
August 19.0% 18.0% 15.9% 18.9% 20.0% 17.6% 20.3% 
September 8.2% 7.9% 7.4% 7.8% 7.7% 9.0% 6.2% 
October 6.5% 6.4% 7.2% 6.8% 6.1% 6.1% 6.5% 
November 4.4% 5.2% 5.6% 4.4% 3.9% 5.1% 4.2% 
December 3.2% 3.4% 3.5% 2.9% 2.4% 2.7% 2.2% 
(Source: National Immunization Survey-Teen). 
Note. Tdap=tetanus, diphtheria, and pertussis booster; Meng=meningococcal vaccine; HPV=human papillomavirus vaccine. 
1Uptake of first dose among female adolescents only. 
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 Table 3. Cyclical Effects in Adolescent Vaccine Uptake  
    Tdap booster Meningococcal vaccine HPV vaccine1 
T 
magnitude 
(RHL[var]) T 
magnitude 
(RHL[var]) T 
magnitude 
(RHL[var]) 
Combined years  12,173,702*  5.1 (0.01)  19,067,776*  10.1 (0.01)  5,037,752*  4.7 (0.01) 
Y
e
a
r
 
2007  3,552,048*  4.6 (0.01)  4,793,365*  7.5 (0.01)  2,145,027*  5.7 (0.01) 
2008  3,099,100*  4.5 (0.01)  5,333,919*  8.3 (0.01)  1,349,452*  4.5 (0.01) 
2009  2,458,182*  5.0 (0.01)  3,873,037*  9.1 (0.01)  876,756*  5.3 (0.01) 
2010  1,654,178*  5.7 (0.01)  2,366,461*  10.5 (0.01)  563,744*  5.7 (0.01) 
2011  868,275*  6.6 (0.01)  1,354,808*  21.2 (0.01)  341,771*  4.8 (0.01) 
(Source: National Immunization Survey-Teen). 
Note. Tdap=tetanus, diphtheria, and pertussis; HPV=human papillomavirus; T=Edwards’ T statistic; RHL=ratio of highest to lowest 
vaccination (i.e., the ratio of frequency of vaccination in the month when it is most common to the month when it is least common); 
var=variance. *p<.001. 
1Uptake of first dose among female adolescents only. 
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 Table 4. Cyclical Effects in Concomitant Adolescent Vaccine Uptake  
    Tdap and Meng Tdap and HPV Meng and HPV All three 
 T  
magnitude 
(RHL[var]) T 
magnitude 
(RHL[var]) T 
magnitude 
(RHL[var]) T 
magnitude 
(RHL[var]) 
Combined years  6,848,772*  5.6 (0.01)  1,504,766*  4.6 (0.01)  1,915,599*  4.2 (0.01)  744,320*  3.3 (0.01) 
Y
e
a
r
 
2007  1,641,649*  5.1 (0.01)  640,471*  6.2 (0.01)  761,522*  4.8 (0.01)  288,103*  4.5 (0.01) 
2008  1,756,694*  4.7 (0.01)  373,947*  4.0 (0.01)  619,119*  4.3 (0.01)  195,484*  3.1 (0.01) 
2009  1,420,718*  4.8 (0.01)  395,753*  7.2 (0.01)  487,682*  6.4 (0.01)  213,425*  4.2 (0.01) 
2010  1,152,333*  7.5 (0.01)  280,421*  10.4 (0.01)  243,709*  5.8 (0.01)  160,424*  5.6 (0.01) 
2011  482,161*  6.9 (0.01)  135,135*  8.3 (0.01)  128,367*  5.2 (0.01)  38,752*  3.3 (0.01) 
(Source: National Immunization Survey-Teen). 
Note. Tdap=tetanus, diphtheria, and pertussis booster; Meng=meningococcal vaccine; HPV=human papillomavirus; T=Edwards’ T 
statistic; RHL=ratio of highest to lowest vaccination (i.e., the ratio of frequency of vaccination in the month when it is most common 
to the month when it is least common); var=variance. *p<.001. 
1Uptake of first dose among female adolescents only. 
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 Supplemental Table S1. Cyclical Effects in Uptake of Adolescent Vaccines and Concomitant Adolescent Vaccine Uptake By State  
    Tdap booster Meningococcal vaccine HPV vaccine1 
N  T  
magnitude 
(RHL[var])  T  
magnitude 
(RHL[var])  T  
magnitude 
(RHL[var]) 
Alabama  1252  6,998*  4.4 (0.01)  8,216*  6.8 (0.01)  3,031*  4.2 (0.01) 
Alaska  1058  1,413*  7.2 (0.01)  1,792*  17.9 (0.01)  695*  6.3 (0.01) 
Arizona  1391  9,413*  3.6 (0.01)  16,821*  4.9 (0.01)  6,685*  5.2 (0.01) 
Arkansas  833  4,033*  7.8 (0.01)  3,657*  15.0 (0.01)  3,046*  37.7 (0.01) 
California  1582  48,407*  4.0 (0.01)  90,966*  7.4 (0.01)  29,461*  4.5 (0.01) 
Colorado  1408  11,533*  5.9 (0.01)  11,910*  12.1 (0.01)  3,239*  4.3 (0.01) 
Connecticut  1588  5,352*  4.1 (0.01)  10,525*  8.8 (0.01)  2,183*  3.4 (0.01) 
Delaware  1409  935*  3.5 (0.01)  1,712*  5.0 (0.01)  499*  3.2 (0.01) 
District of Columbia 1517  308*  3.0 (0.01)  1,347*  7.9 (0.01)  469*  7.0 (0.01) 
Florida  1374  30,650*  6.2 (0.01)  36,766*  8.8 (0.01)  10,910*  4.4 (0.01) 
Georgia  1258  12,250*  3.9 (0.01)  21,645*  7.5 (0.01)  6,479*  5.6 (0.01) 
Hawaii  1143  1,718*  5.2 (0.01)  2,059*  5.9 (0.01)  1,025*  4.6 (0.01) 
Idaho  903  2,640*  7.7 (0.01)  3,316*  15.4 (0.01)  2,054*  56.9 (0.01) 
Illinois 2748  21,718*  5.2 (0.01)  34,551*  16.4 (0.01)  6,925*  4.8 (0.01) 
Indiana  1584  8,551*  3.7 (0.01)  16,902*  7.3 (0.01)  3,611*  5.0 (0.01) 
Iowa  1074  4,544*  5.7 (0.01)  5,005*  7.9 (0.01)  2,439*  5.7 (0.01) 
Kansas  1248  6,174*  6.2 (0.01)  5,521*  13.1 (0.01)  2,820*  12.3 (0.01) 
Kentucky  1020  6,264*  6.5 (0.01)  6,779*  8.0 (0.01)  1,670*  3.4 (0.01) 
Louisiana  1387  8,867*  6.6 (0.01)  16,836*  15.6 (0.01)  3,653*  4.3 (0.01) 
Maine  1309  1,168*  3.1 (0.01)  2,294*  5.4 (0.01)  670*  3.5 (0.01) 
Maryland  1384  9,519*  6.3 (0.01)  13,793*  6.8 (0.01)  3,139*  3.9 (0.01) 
Massachusetts  1479  5,877*  3.1 (0.01)  20,215*  8.2 (0.01)  5,903*  4.5 (0.01) 
Michigan  1334  14,617*  5.1 (0.01)  19,849*  6.1 (0.01)  6,099*  4.4 (0.01) 
Minnesota  1156  8,162*  5.3 (0.01)  12,251*  13.3 (0.01)  5,061*  8.5 (0.01) 
Mississippi  686  1,926*  4.0 (0.01)  2,822*  8.1 (0.01)  965*  4.1 (0.01) 
Missouri  1266  10,394*  6.3 (0.01)  10,037*  7.4 (0.01)  3,977*  5.4 (0.01) 
Montana 1086  1,615*  6.2 (0.01)  1,183*  8.4 (0.01)  910*  12.3 (0.01) 
Nebraska  1153  2,588*  4.7 (0.01)  4,398*  10.6 (0.01)  814*  3.2 (0.01) 
Nevada  1183  5,973*  6.5 (0.01)  9,005*  40.3 (0.01)  4,328*  98.2 (0.01) 
New Hampshire  1359  1,435*  3.0 (0.01)  3,618*  7.4 (0.01)  1,282*  4.9 (0.01) 
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 New Jersey  1614  19,648*  5.7 (0.01)  36,139*  9.6 (0.01)  7,210*  6.9 (0.01) 
New Mexico  1441  4,531*  5.1 (0.01)  4,798*  9.5 (0.01)  777*  2.5 (0.01) 
New York  2715  39,260*  4.5 (0.01)  43,429*  6.1 (0.01)  22,260*  7.6 (0.01) 
North Carolina  1260  15,837*  4.3 (0.01)  18,101*  7.2 (0.01)  9,634*  8.9 (0.01) 
North Dakota  1242  1,335*  5.7 (0.01)  2,235*  11.8 (0.01)  455*  6.1 (0.01) 
Ohio  1137  12,420*  4.1 (0.01)  20,629*  5.8 (0.01)  9,375*  6.5 (0.01) 
Oklahoma  981  5,379*  6.3 (0.01)  6,440*  11.0 (0.01)  2,987*  5.8 (0.01) 
Oregon  1226  5,783*  5.0 (0.01)  6,341*  9.6 (0.01)  2,976*  5.0 (0.01) 
Pennsylvania 2907  20,082*  5.1 (0.01)  38,034*  9.0 (0.01)  11,219*  4.8 (0.01) 
Rhode Island  1438  1,153*  4.0 (0.01)  1,963*  6.1 (0.01)  708*  2.9 (0.01) 
South Carolina  909  3,834*  3.6 (0.01)  6,941*  7.3 (0.01)  1,011*  2.5 (0.01) 
South Dakota  954  1,626*  11.7 (0.01)  1,690*  19.3 (0.01)  2,735*  50.0 (0.01) 
Tennessee  1181  7,965*  5.1 (0.01)  15,161*  15.8 (0.01)  3,980*  5.3 (0.01) 
Texas  6236  53,091*  6.0 (0.01)  74,826*  13.7 (0.01)  20,190*  6.4 (0.01) 
Utah  1085  8,000*  13.3 (0.01)  7,343*  24.6 (0.01)  2,457*  10.3 (0.01) 
Vermont  1441  947*  3.7 (0.01)  1,205*  7.4 (0.01)  527*  4.6 (0.01) 
Virginia  1219  13,168*  5.4 (0.01)  15,761*  7.7 (0.01)  7,166*  6.6 (0.01) 
Washington  1291  15,848*  6.1 (0.01)  16,774*  7.6 (0.01)  7,312*  4.9 (0.01) 
West Virginia  940  1,708*  4.3 (0.01)  2,729*  9.2 (0.01)  1,648*  8.8 (0.01) 
Wisconsin  1321  14,340*  5.9 (0.01)  17,355*  12.6 (0.01)  5,338*  5.7 (0.01) 
Wyoming 1221  627*  3.8 (0.01)  1,217*  12.0 (0.01)  512*  6.2 (0.01) 
(Source: National Immunization Survey-Teen). 
Note. Tdap=tetanus, diphtheria, and pertussis; HPV=human papillomavirus; T=Edwards’ T statistic; RHL=ratio of highest to lowest 
vaccination (i.e., the ratio of frequency of vaccination in the month when it is most common to the month when it is least common) 
(i.e., the ratio of frequency of vaccination in the month when it is most common to the month when it is least common); var=variance. 
Parents reported state of residence at the time of participation in NIS-Teen. *p<.001. 
1Uptake of first dose among female adolescents only. 
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Figure 7. Summer peaks in adolescent vaccine uptake in United States (black lines) and 
states (gray lines). (A) Tdap booster, (B) meningococcal vaccine, and (C) HPV vaccine (first 
dose, among girls). Uptake from 2007 to 2012 combined and standardized at 100 per month. 
(Source: National Immunization Survey-Teen.)  
 
 Figure 8. Summer peaks in uptake of Tdap booster, meningococcal vaccine, and HPV vaccine (first dose, among girls) in the United 
States. Uptake from 2007 to 2011, separately, and standardized at 100 per month.  
 (Source: National Immunization Survey-Teen.) 
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 Supplemental Figure S1. Summer peaks in concomitant uptake of Tdap booster, meningococcal vaccine, and HPV vaccine (first dose, 
among girls) in the United States. Uptake from 2007 to 2011, separately, and standardized at 100 per month.  
(Source: National Immunization Survey-Teen.) 
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CHAPTER 6: STATES’ SCHOOL ENTRY REQUIREMENTS, SUMMER 
INCREASES IN VACCINATION, AND COVERAGE WITH RECOMMENDED  
ADOLESCENT VACCINES: 2007 TO 2012 
Introduction 
Since 2006, the United States has introduced recommendations for three vaccines for 
routine administration to adolescents: tetanus, diphtheria, and pertussis (Tdap) booster; 
meningococcal vaccine; and human papillomavirus (HPV) vaccine.15 As of 2013, coverage 
reached 86% (Tdap booster), 78% (meningococcal vaccine), and 57% (initiation of the three-
dose HPV vaccine series among adolescent girls).118 However, these national figures mask 
considerable variation among states: Tdap vaccination ranges from 60% (Mississippi) to 96% 
(Rhode Island), meningococcal vaccination from 40% (Arkansas) to 94% (North Dakota), 
and HPV vaccine initiation among girls from 40% (Kansas) to 77% (Rhode Island).118 
Understanding the factors driving these differences has important implications for achieving 
adequate adolescent vaccination coverage across the United States. 
States’ vaccination school entry requirements37 are one potential explanation for 
variation in vaccination coverage. These policies require that students receive vaccines 
before entering a certain grade in middle or high school, with exemptions allowed for 
medical reasons and, in some states, religious or philosophical reasons. As of Fall 2014, 47 
states had school entry requirements in effect for Tdap, 20 for meningococcal vaccine, and 2 
for HPV vaccine (initiation among adolescent girls).37 These school entry requirements likely 
lead to increases in coverage for the vaccines they target,47,112,119-121 as well as spillover 
increases in coverage for non-targeted vaccines.51,52 The former effect is the desired outcome 
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of vaccination requirements, and the latter effect may arise due to concomitant vaccination—
receipt of two or more vaccine(s) during the same healthcare visit. That is, adolescents 
seeking a vaccine targeted by a school entry requirement may concomitantly receive other 
vaccines, leading to increases in coverage for vaccines not targeted by the policy. 
School entry requirements likely increase vaccination behaviors prior to the 
beginning of the academic year. A background level of vaccination throughout the entire 
calendar year persists, but these policies may increase adolescent vaccination during summer 
months.112,113 In our previous study of vaccination cycles, we found that adolescent 
vaccination is most common in June, July, and August, when healthcare providers deliver 
about 40% of individual and concomitant vaccinations to U.S. adolescents.122 In turn, these 
summer vaccination peaks may increase overall coverage. 
In the present study, we evaluated the longitudinal effects of vaccination school entry 
requirements on coverage for targeted and non-targeted vaccines. In addition, we tested 
whether summer peaks in adolescent vaccination accounted for the impact of school entry 
requirements on vaccination coverage.  
Methods 
Data Sources 
Data on vaccination school entry requirements came from the Immunization Action 
Coalition (IAC), which publishes information on school entry requirements compiled from 
health departments in all 50 states and Washington, D.C. (hereafter collectively referred to as 
“states” for simplicity).37 The database includes an indication of whether each state has a 
school entry requirement for Tdap, meningococcal, or HPV vaccination and, if so, when it 
became effective.47,52,123 
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Data on vaccination coverage and on summer increases in vaccination came from the 
National Immunization Survey-Teen (NIS-Teen). Each year, the CDC implements NIS-Teen 
to estimate national- and state-level coverage with each adolescent vaccine.61 NIS-Teen 
interviewers administered phone surveys to a population-based sample of caregivers 
(hereafter referred to as “parents”) of 13- to 17-year-old adolescents. After randomly 
selecting one adolescent in each household, interviewers gathered demographic and health 
information about the child. At the end of the survey, interviewers asked for parents’ consent 
to contact the adolescents’ primary healthcare providers to verify vaccination history. Since 
2008, NIS-Teen has collected provider-verified vaccination data for about 20,000 adolescents 
each year, for a total of 99,921 adolescents over the five study years. 
Data collection for NIS-Teen was approved by the National Center for Health 
Statistics (NCHS) Research Ethics Review Board. Analysis of de-identified data from the 
survey is exempt from the federal regulations for the protection of human research 
participants. Analysis of restricted data through the NCHS Research Data Center is also 
approved by the NCHS ERB. The University of North Carolina Institutional Review Board 
exempted this study from review.  
Measures 
School entry requirements. Separately for Tdap, meningococcal vaccine, and HPV 
vaccine, we coded states as 1 if they had a school entry requirement in effect by the fall 
semester of each year from 2007 to 2012, and we coded states as 0 if they did not. All states 
had complete data for all study years. 
Adolescent vaccination coverage. We measured coverage for Tdap vaccination, 
meningococcal vaccination, and HPV vaccination (first dose among females) using NIS-
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Teen’s annual state-level estimates of coverage among 13- to 17-year-olds.5,62-65 Importantly, 
these estimates are based on the same samples as the ones used in the present study. 
Summer vaccination peaks. We coded the month and year during which adolescents 
received vaccines. For each vaccination outcome, we excluded from analysis any adolescent 
without provider-verified data on receipt of that vaccine. For participants who had received at 
least two adolescent vaccines, we determined whether they had received the doses 
concomitantly, i.e., on the same day.31 We measured concomitant vaccination for each 
potential combination of adolescent vaccines. We descriptively inspected cycles in 
adolescent vaccination by calculating the average percentage of vaccine doses administered 
each month for states with and without school entry requirements. Consistent with previous 
work,122 we found that vaccination was most common in June, July, and August (see Figure 9 
for an illustrative example of vaccination across months). 
Then, for each single and concomitant vaccination outcome, we calculated the 
percentage of doses administered in these three months compared to the entire year. If 
vaccination patterns were constant across the calendar year, the summer vaccination 
percentage would equal .252 (because June, July, and August have 92 days, out of 365 total 
days); amounts over that figure would indicate excess vaccination in the summer months 
relative to the rest of the year. We calculated this percentage separately for each state, for 
each study year, for each vaccination outcome. Due to small cell sizes, we excluded from 
analysis summer peaks for vaccines delivered in 2012. Calculations of summer vaccination 
peaks incorporated NIS-Teen sampling weights to account for non-equal probability of 
selection. 
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For HPV vaccination, we measured initiation of the three-dose series among female 
adolescents only, because the CDC began recommending HPV vaccine for routine 
administration in girls in 200715 but not in boys until 2011.4 Consequently, the summer 
vaccination peaks for HPV vaccination and for two concomitant vaccination outcomes (Tdap 
and HPV vaccine; meningococcal and HPV vaccines) reflect patterns of uptake only among 
girls.  
Analytic Strategy 
Analyses examined Tdap and meningococcal vaccination policies. We excluded HPV 
vaccination policies because only two states had them in effect during the entire study period. 
Because the effects of school entry requirements may not have emerged in the same year as 
policy adoption, and because of the time required to achieve universal implementation and 
for effects to spread through the population, we calculated the association of school entry 
requirements with summer vaccination peaks in a given year and with vaccination coverage 
in the following year (i.e., a one-year lag). Our preliminary analyses found that these lagged 
models provided a better fit to the observed data than non-lagged models (data not shown). 
Next, we conducted formal mediation analysis using generalized estimating equations 
to test whether states’ vaccination school entry requirements increased summer vaccination 
peaks, which in turn increased overall coverage. We used bootstrapping to examine the 
statistical significance of the mediated effect, following the steps outlined by Hayes.124 
Specifically, we ran three models: (1) estimating the main effect between school entry 
requirements and coverage (c path), (2) estimating the effect between school entry 
requirements and summer vaccination peaks (a path), and (3) the simultaneous effects of 
school entry requirements and summer vaccination peaks on coverage (c’ and b paths, 
67 
respectively). We calculated the indirect (mediated) effect by multiplying the parameter 
estimates for the a and b paths. Next, we sampled with replacement among the observed data 
to create 1,000 simulated datasets. Then, we repeated the analysis described previously for 
each simulated dataset, calculated the resulting indirect effect, and examined the percentile-
based bootstrapped 95% confidence interval. We repeated these analyses for each 
combination of school entry requirements and coverage, using summer peaks for the 
vaccines under study in that model.  
Models controlled for school entry requirements, vaccination peaks, and coverage 
from previous years as well as the presence of state school entry requirements for adolescent 
vaccines besides the one under study (e.g., models testing the effects of Tdap vaccination 
requirements controlled for the presence of meningococcal vaccination and HPV vaccination 
requirements). We weighted states’ observations according to the sample sizes included in 
NIS-Teen. We implemented mediation analysis with PROC GENMOD and resampling with 
PROC SURVEYSELECT in SAS version 9.2 (Cary, NC). Statistical tests used a two-tailed p 
value of .05.  
As a supplementary analysis, we tested the invariance of the policies’ effects over 
time by including interaction terms for study year and each of the explanatory variables (in 
the observed dataset only). We then used Wald tests to examine the joint contribution of each 
set of interaction terms to the overall fit of the models. If the Wald tests did not indicate that 
the explanatory variables interacted with study year, we dropped them from the model. 
Results 
From 2007 to 2012, between 7 and 42 states had Tdap vaccination school entry 
requirements, between 0 and 14 states had meningococcal vaccination requirements, and 2 
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states had HPV vaccination requirements (Table 5). National vaccination coverage estimates 
ranged from 30% to 85% for Tdap, 32-74% for meningococcal vaccine, and 25-54% for 
HPV vaccine. Averaged across the study years, summer vaccination peaks were between 
53% and 55% for all outcomes.  
Impact of Tdap School Entry Requirements  
States with Tdap vaccination school entry requirements had higher Tdap vaccination 
coverage than states without such policies (77% versus 54%, respectively, p<.001; Figure 
10), and they had higher summer Tdap vaccination peaks (52% versus 46%, p<.001; Figure 
11) (Table 6). In addition, these states also had higher meningococcal vaccination coverage 
(67% versus 51%, p<.001; Figure 10) and higher summer peaks of concomitant vaccination 
with Tdap and meningococcal vaccines (54% versus 48%, p<.001; Figure 11). Finally, these 
states also had higher HPV vaccination coverage (52% versus 44%, p<.001; Figure 10) and 
higher summer peaks of concomitant vaccination with Tdap and HPV vaccines (52% versus 
46%, p<.001; Figure 11). 
Impact of Meningococcal Vaccination School Entry Requirements 
States with meningococcal vaccination school entry requirements had higher 
meningococcal vaccination coverage than states without such policies (81% versus 54%, 
respectively; p<.001; Figure 10), and they had higher summer meningococcal vaccination 
peaks (55% versus 48%, p<.001; Figure 11) (Table 6). In addition, these states also had 
higher Tdap vaccination coverage (80% versus 62%, p<.001; Figure 10) and higher summer 
peaks of concomitant vaccination with meningococcal and Tdap vaccines (57% versus 48%, 
p<.001; Figure 11). Finally, these states also had higher HPV vaccination coverage (53% 
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versus 47%, p<.001; Figure 10) and higher summer peaks of concomitant vaccination with 
meningococcal and HPV vaccines (51% versus 46%, p<.001; Figure 11). 
Mediation and Additional Analyses 
Summer vaccination peaks did not mediate the relationships of either vaccination 
requirement and vaccination coverage for Tdap, meningococcal, or HPV (all p>.05; Table 4). 
In supplementary analyses, study year did not interact with (1) school entry requirements or 
(2) summer vaccination peaks in predicting vaccination coverage (all Wald chi-square 
statistics<4, all p>.25). 
Conclusion 
In a five-year sample of adolescents from all 50 states and Washington, D.C., we 
found that vaccination school entry requirements consistently led to higher vaccination 
coverage and higher summer vaccination peaks. School entry requirements account for some 
of the substantial variation in coverage among states. However, summer vaccination peaks 
did not explain the main effect between school entry requirements and coverage.  
States’ vaccination school entry requirements were associated with higher coverage 
for their targeted vaccines: a 23% absolute increase in Tdap vaccination and a 27% absolute 
increase in meningococcal vaccination. Previous studies have demonstrated similar though 
smaller magnitudes for policies targeting Tdap vaccination47,51,112 and meningococcal 
vaccination.47,121 In contrast to any of the previous studies, we used longitudinal analyses that 
included a lag of one year and controlled for the previous years’ measurements to help 
establish the temporality of the relationships. Vaccination school entry policies appear to 
achieve their intended goals of increasing coverage. However, eight states still fall short of 
Healthy People 2020 guidelines for Tdap vaccination and 32 states fall short of the guidelines 
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for meningococcal vaccination,118 so more progress is needed to achieve optimal levels of 
coverage.  
School entry requirements also had smaller, spillover effects of increasing coverage 
for non-targeted vaccines. Specifically, Tdap requirements were associated with a 16% 
absolute increase in meningococcal vaccination and an 8% absolute increase in HPV 
vaccination. Meningococcal vaccination requirements were associated with an 18% absolute 
increase in Tdap vaccination and a 6% absolute increase in HPV vaccination. Previous 
studies have demonstrated the spillover effects of Tdap requirements on meningococcal 
vaccination51,112 and HPV vaccination,52 but to our knowledge, no studies have yet 
investigated spillover effects of meningococcal vaccination requirements. As such, 
vaccination requirements have the unintended benefits of improving other vaccination 
outcomes. This finding is especially pertinent for HPV vaccination, given both the political 
difficulties in adopting school entry requirements for this vaccine36,39,125 and low rates of 
initiation and completion of the vaccine series among U.S. adolescents (as of 2013, 57% and 
38% among females, respectively, and 35% and 14% among males, respectively).118 That is, 
absent HPV vaccination school entry requirements, implementing requirements for Tdap or 
meningococcal vaccine may lead to increases in HPV vaccination coverage. 
Vaccination school entry requirements were also positively associated with increases 
in summer peaks, the percentage of single and concomitant vaccine doses administered in 
summer months. For example, if vaccination were equally distributed over the year, the 
summer peak would equal 25%, but even in states without Tdap school entry requirements, 
healthcare providers administered 43% of HPV vaccine doses in the summer months. Even 
more striking, in states with Tdap requirements, providers administered 49% of HPV vaccine 
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doses in the summer (see Figure 11). The absolute difference of 6% between the latter two 
percentages speaks to the potential change in vaccination behaviors during the summer 
months that healthcare providers may see immediately after a state institutes a school entry 
requirement. Anticipating this change could assist providers in preparing for this increased 
demand, perhaps through capacity-expanding initiatives such as adopting standing orders for 
recommended vaccines.126  
Finally, summer vaccination peaks demonstrated positive associations with coverage. 
We could not determine if adolescents’ demand for vaccines or healthcare providers’ ability 
to supply them limited the summer vaccination peaks. However, results from our study 
illustrate that states with healthcare systems that delivered more adolescent vaccines during 
summer months had higher overall coverage. This relationship held true for summer peaks of 
single or concomitant vaccination. As a result, interventions or quality improvement 
programs targeting adolescent vaccination that take place in the spring may be particularly 
effective in supporting higher summer vaccination peaks and, as a result, higher coverage. 
Future research is needed to examine the ideal timing and duration of programs that prepare 
healthcare providers for summer increases in adolescent vaccination. 
However, findings from the present study did not support our hypothesis that summer 
vaccination peaks would mediate, or explain, the relationship between school entry 
requirements and coverage. Although all of these variables were interrelated, some other 
variable(s) must explain the association of school entry requirements and coverage. One 
viable intervening mechanism is the expansion of public funding for vaccination that 
accompanies adoption of a school entry requirement. That is, when states require students to 
receive certain vaccines, they must devote public funds to support vaccination for children 
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who cannot afford them.32 If cost limited the uptake of adolescent vaccines (which several 
studies have suggested is the case for HPV vaccine74,85,86), states that expand public funding 
for vaccination may subsequently see increases in coverage. Additional studies are needed to 
explicate the causal pathway between these variables. 
Study strengths include a large sample size (almost 100,000 adolescents) from a high-
quality national dataset.61 Healthcare providers verified vaccine uptake for participants, 
increasing our confidence in the validity of these measures. Most previous studies of school 
entry requirements have focused on policies that require Tdap vaccination, but we also 
investigated the effects of school entry requirements for meningococcal vaccination. 
Although previous studies of vaccination school entry requirements have used cross-sectional 
designs, we used a longitudinal design to disentangle the temporal relationships among study 
variables and examine the consistency of these relationships over time. Study limitations 
include our inability to randomize states to adopting vaccination school entry requirements; 
because of this limitation, we were unable to eliminate the possibility that other variables 
confounded the observed relationships. In addition, due to small cell sizes, we could not 
analyze vaccination peaks in 2012, but with continuing data collection (i.e., survey years 
2013 and 2014), future studies will be able to evaluate more recent vaccination peaks and 
their relationships with school entry requirements and coverage. 
In conclusion, we found consistent, positive relationships between vaccination school 
entry requirements, the summer peaks in single and concomitant adolescent vaccination, and 
Tdap, meningococcal, and HPV vaccination coverage. These results suggest that school entry 
requirements lead to increases in uptake for targeted vaccines as well as spill-over increases 
in uptake for other vaccines. In addition, these results point to specific times when vaccine 
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promotion efforts may be particularly effective, i.e., immediately after a state adopts a school 
entry requirement and in the months before the summertime increase in vaccination demand. 
Addendum 
In addition to the research described in this chapter, I originally proposed examining 
the relationship between HPV vaccination school entry requirements and HPV vaccination 
coverage, and whether cycles in HPV vaccination mediated that association. I have described 
those analyses next.  
I also discuss possible alternative mediation pathways that may explain why, despite 
the strong relationships among all the study variables, the mediation analysis did not find that 
summer vaccination peaks attenuated the association between vaccination requirements and 
coverage.  
Impact of HPV Vaccination School Entry Requirements 
States with HPV vaccination school entry requirements had higher HPV vaccination 
coverage than states without such policies (50% versus 48%, respectively; p<.001), and they 
had higher summer HPV vaccination peaks (49% versus 45%, p<.001). However, summer 
vaccination peaks did not mediate the relationships of HPV vaccination requirements and 
HPV vaccination coverage (p>.05). 
Future Research on Alternative Mediation Pathways 
The results of the present analysis did not support my hypothesis that summer 
vaccination peaks would mediate the relationship between school entry requirements and 
coverage (panel A in Figure S2). Instead, the results suggest that school entry requirements 
are associated with summer peaks and coverage, but these latter variables are only spuriously 
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(i.e., non-causally) related (panel B in Figure S2). At least two other possibilities exist for the 
actual relationships among these variables.  
In the first possibility (panel C in Figure S2), vaccination coverage levels precede 
school entry requirements, which only become politically feasible after a critical mass of 
vaccination occurs (and attendant pro-vaccination norms spread through the population). 
After the school entry requirements go into effect, summer peaks increase because families 
become motivated to seek vaccinations in the summer months to come into compliance with 
the policies. 
In the second possibility (panel D in Figure S2), school entry requirements lead to 
increases in coverage as families seek vaccinations to comply with the policies. As the 
absolute numbers of vaccinating adolescents increases, so too does the absolute number of 
doses administered in the summer (and, subsequently, the percentage of doses administered 
in the summer). 
Going forward, I plan to evaluate both of these alternative models against the 
observed data to determine which provides a more valid description of the actual 
relationships among the study variables. In addition, I will recalculate summer vaccination 
peaks only among adolescents in a restricted age range (i.e., 11–13 years) that is most often 
the target of school entry requirements. I will rerun the mediation analysis with this measure 
of summer peaks that is more sensitive to change as a result of a new school entry 
requirement than the measure of peaks for the entire adolescent age group. 
 
 Table 5. The Number of States With School Entry Requirements, Mean Summer Vaccination Peaks, and Overall Vaccination 
Coverage  
  Tdap Meng HPV1 
Tdap and 
Meng 
Tdap and 
HPV1 
Meng and 
HPV1 
Year 
States with 
school entry 
requirements 
Summer 
vaccinatio
n peak 
(%) 
Vaccination 
coverage 
(%) 
States with 
school entry 
requirements 
Summer 
vaccination 
peak (%) 
Vaccination 
coverage 
(%) 
States with 
school entry 
requirements 
Summer 
vaccination 
peak (%) 
Vaccination 
coverage 
(%) 
Summer 
vaccination 
peak (%) 
Summer 
vaccination 
peak (%) 
Summer 
vaccination 
peak (%) 
2007 7 44.8 30.4 0 45.6 32.4 2 41.9 25.1 46.3 45.9 47.8 
2008 16 43.3 40.8 3 44.0 41.8 2 38.9 37.2 45.3 43.1 42.7 
2009 24 51.9 55.6 8 52.2 53.6 2 49.3 44.3 53.4 53.2 50.4 
2010 32 66.8 68.7 10 68.4 62.7 2 69.6 48.7 67.7 70.0 69.3 
2011 38 61.2 78.2 13 61.8 70.5 2 62.6 53.0 60.2 61.6 61.0 
2012 42 -- 84.6 14 -- 74.0 2 -- 53.8 -- -- -- 
Mean 27 53.6 65.5 8 54.4 58.9 2 52.5 47.9 54.6 54.8 54.2 
 
Note. Tdap = tetanus, diphtheria, and pertussis booster; HPV = human papillomavirus vaccine; Meng = meningococcal vaccine. 
Vaccination coverage estimates come from NIS-Teen.61 Summer vaccination peaks from 2012 suppressed due to small cell sizes. 
1HPV vaccine initiation (i.e., receipt of ≥1 dose of the 3-dose series) measured among female adolescents only. 
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 Table 6. Summary of Main Effects and Indirect Effects of Summer Vaccination Peaks on the Relationship Between State School Entry 
Requirements and Adolescent Vaccination Coverage 
IV Mediator DV IV to DV IV to Mediator Mediator to DV Mediated effect 
School 
entry 
req. 
Summer 
vaccination 
peak 
Vaccination 
coverage beta SE beta SE beta SE beta 
Percentile-based 
bootstrapped  
95% CI 
Tdap Tdap Tdap 0.467 (0.003)* 0.088 (0.003)* 1.007 (0.016)* 0.089 (-0.077, 0.295) 
Tdap Tdap/Meng Meng 0.018 (0.004)* 0.094 (0.004)* 1.668 (0.014)* 0.157 (-0.203, 0.466) 
Tdap Tdap/HPV HPV 0.149 (0.003)* 0.010 (0.006)* 0.358 (0.007)* 0.003 (-0.161, 0.175) 
   
Meng Meng Meng 0.803 (0.006)* 0.045 (0.003)* 2.201 (0.020)* 0.099 (-0.371, 0.500) 
Meng Tdap/Meng Tdap 0.041 (0.005)* 0.163 (0.005)* 0.851 (0.013)* 0.138 (-0.074, 0.366) 
Meng Meng/HPV HPV 0.105 (0.004)* 0.143 (0.006)* 0.455 (0.008)* 0.065 (-0.221, 0.281) 
 
Note. IV = independent variable; DV = dependent variable; Tdap = tetanus, diphtheria, and pertussis booster; Meng = meningococcal 
vaccine; HPV = human papillomavirus vaccine; SE = standard error; CI = confidence interval. HPV vaccine initiation (i.e., receipt of 
≥1 dose of the 3-dose series) measured among female adolescents only.  
*p<.001, others are not significant at p<.05. 
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Figure 9. Percentage of tetanus, diphtheria, and pertussis (Tdap) booster doses administered 
per month for states with and without school entry requirements for Tdap, averaged across 
study years.  
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Figure 10. Vaccination coverage for states with and without school entry requirements for 
tetanus, diphtheria, and pertussis booster (Tdap, panel A) and meningococcal vaccine (Meng, 
panel B); HPV = human papillomavirus vaccine initiation (females only).  
Error bars show standard errors.  
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Figure 11. Summer vaccination peaks for states with and without school entry requirements 
for tetanus, diphtheria, and pertussis booster (Tdap, panel A) and meningococcal vaccine 
(Meng, Panel B); HPV = human papillomavirus vaccine initiation (females only).  
Error bars show standard errors.  
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Supplemental Figure S2. Conceptual models depicting possible relationships among study 
variables: hypothesized relationships (Panel A); observed relationships (Panel B); first 
alternative, with vaccination coverage preceding adoption of school entry requirements and 
increases in summer peaks (Panel C); and second alternative, with school entry requirements 
and vaccination coverage preceding summer peaks (Panel D). 
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CHAPTER 7: VACCINATION POLICIES, PATIENT-PROVIDER 
COMMUNICATION, AND UPTAKE OF ADOLESCENT VACCINES 
Introduction 
National guidelines recommend that adolescents routinely receive three vaccines: 
tetanus, diphtheria, and pertussis booster (Tdap); meningococcal vaccine; and human 
papillomavirus (HPV) vaccine.15 Healthy People 2020 sets the goal for 80% coverage with 
each adolescent vaccine among 13- to 15-year-old adolescents,27 but current coverage for 
meningococcal vaccine and HPV vaccine falls short of this benchmark.118 
A socio-ecological analysis of this problem127 would suggest that factors from the 
policy, community, institutional, interpersonal, and intrapersonal levels independently and 
interactively influence health behaviors. Most research on vaccination has focused on 
intrapersonal characteristics of adolescents or their parents, with relatively few studies 
examining factors at higher ecological levels that could influence decision making such as 
states’ vaccine school entry requirements (policy level) or communication with healthcare 
providers (interpersonal level). 
As Fall 2014, 47 states (including Washington, D.C.) had policies requiring 
adolescents to receive Tdap before entering a particular grade in school, 20 states had 
requirements for meningococcal vaccine, and 2 states had requirements for HPV vaccine.37 
Adolescents are more likely to receive Tdap47,51 or meningococcal vaccine47,121 if they live in 
states with school entry requirements for these vaccines than in other states. No studies we 
are aware of have yet quantified the effects of HPV vaccination requirements, although 
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previous research has demonstrated their acceptability to parents.42,43 In states with these 
requirements, parents and adolescents may be more likely to receive targeted vaccines 
because uptake becomes a default behavior, that is, one that occurs unless an individual 
makes a conscious decision to act against it.48 A vaccination default may increase uptake if 
seeking an exemption from the school entry requirement is more burdensome than 
vaccinating.33,48,49 Thus, in the current study, we hypothesized that states with school entry 
requirements would have higher adolescent vaccination coverage than states without such 
requirements (Hypothesis 1). 
Although research has highlighted the singular influence a provider’s 
recommendation can have on adolescent vaccination coverage,6,70 fewer studies have 
investigated the style of a provider’s communication with parents and adolescents. Ethicists 
and legal scholars have encouraged clinicians to use a collaborative or shared approach to 
communication in primary care to preserve patients’ decision making 
autonomy,99,103,107,128,129 especially when discussing healthcare options that are complex or 
lack professional consensus.130-132 For example, Charles and Gafni100,101,133 proposed a 
framework that articulates the necessary conditions for collaboration, namely, bidirectional 
exchange of information between patients and providers, opportunity for both parties to 
deliberate on the best course of action, and coming to a decision that both parties support. 
Use of a collaborative communication style has been associated with improved clinical 
outcomes compared to more directive communication styles.103,106  
However, many clinicians opt for a directive communication style due to concerns 
about the time needed to engage in collaborative communication.128,134 Collaborative 
communication may be unnecessary for decisions about healthcare services, such as 
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vaccination, that are minimally invasive, highly efficacious, and marked by professional 
consensus.107,132,135 Informed consent regulations ensure that patients and providers will 
always communicate prior to vaccination, but a less collaborative communication style may 
discourage parents from opting out of vaccination.69,108 For example, Opel and colleagues108 
found that 74% of parents accepted flu vaccination for their infants if providers used a 
directive communication style versus 4% of parents whose providers used a collaborative 
style.  
Thus, ethical and empirical scholarship diverges in regard to the best way for 
providers to communicate with parents to achieve high levels of vaccine acceptance. 
Informed by this previous research on communication style, we created two competing 
hypotheses about the relationship between collaboration and vaccination. We hypothesized 
that collaborative patient-provider communication would be associated with higher 
adolescent vaccination coverage than other types of communication (Hypothesis 2a). 
Collaborative communication offers parents and adolescents adequate time to process 
information about vaccination and provides physicians with the opportunity to persuade 
hesitant patients, which could lead to increased levels of uptake. In contrast, we hypothesized 
that collaborative patient-provider communication would be associated with lower adolescent 
vaccination coverage than other types of communication (Hypothesis 2b). Collaborative 
communication affords parents and adolescents more opportunities to object and opt out of 
vaccination, which could lead to decreased levels of uptake. 
The influence of provider communication style may vary depending on whether an 
adolescent lives in a state with a vaccination school entry requirement. To comply with 
school entry requirements in states with such policies, parents and adolescents may choose to 
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vaccinate regardless of providers’ communication style. That is, states’ vaccine school entry 
requirements may dampen the effects of patient-provider communication style on adolescent 
vaccination. As such, we hypothesized that regardless of the direction of the relationship 
between communication style and adolescent vaccination the effect would be moderated by 
states’ vaccine school entry requirements such that communication style would be less 
influential in states with vaccine requirements than in states without vaccine requirements 
(Hypothesis 3).  
Methods 
Procedures 
Data came from the 2010 National Immunization Survey (NIS)-Teen implemented by 
the CDC.61 NIS-Teen included phone interviews with a national sample of caretakers of 13- 
to 17-year-old adolescents (hereafter called “parents”), during which parents reported the 
vaccination history of a randomly selected adolescent in the household. At the end of the 
interview, NIS-Teen staff asked for consent to contact the adolescents’ primary healthcare 
providers to verify vaccination history with written surveys. Among 39,811 eligible parents 
that NIS-Teen staff contacted, 32,429 (82% of those contacted) completed the interview. Of 
these, 23,738 (73% of those interviewed) consented to provider verification, and NIS-Teen 
staff mailed surveys to the clinics of all identified providers. Clinics returned surveys on the 
vaccination history of 19,257 adolescents (81% of those who consented). NIS-Teen staff 
developed sampling weights for each participant in the sample with provider-verified 
vaccination history to account for non-equal probability of selection. 
During the final two quarters of the 2010 survey year, 11,860 participants completed 
the Parental Attitudes Module, a supplementary set of items measuring parents’ attitudes, 
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beliefs, and experiences regarding adolescent vaccines, including patient-provider 
communication. Among these participants, 9,194 (77.5%) had provider verification of 
vaccination history. We used data from this sample in the current study. We excluded 
participants who had missing data for all communication items (n=173), for a final analytic 
sample of 9,021. 
The National Center for Health Statistics (NCHS) Research Ethics Review Board 
approved data collection for NIS-Teen. Analysis of de-identified data from the survey is 
exempt from federal regulations for the protection of human research participants. Analysis 
of restricted data through the NCHS Research Data Center is also approved by the NCHS 
ERB. The Institutional Review Board at the University of North Carolina exempted this 
study from review. 
Measures 
School entry requirements. Parents reported state of residence (including Washington, 
D.C., hereafter referred to as a “state” for the sake of simplicity) in the NIS-Teen phone 
interview. The Immunization Action Coalition37 (IAC) compiles data from state health 
departments on whether they have policies requiring students to receive vaccines prior to 
entry into certain grades in school and, if so, when the policies went into effect. Separately 
for each vaccine, we used this database to code states as 1 if they had a school entry 
requirement in effect by the fall semester of 2010 (the year of NIS-Teen data examined for 
this study) and 0 if they did not.  
Patient-provider communication. Parents answered three items about conversations 
with their adolescents’ healthcare providers about each vaccine (total of nine items). These 
items mapped on to the components of collaboration proposed by the Charles and Gafni’s 
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framework of patient-provider communication:100,101,133 information exchange, deliberation, 
and decision.  
Items began with “At visits made for [teen name]’s vaccinations, did [his/her] 
healthcare provider…” and concluded with “…talk to you about [vaccine]?” (information 
exchange); “…give you enough time to discuss [vaccine]?” (deliberation); and “…play a role 
in your decision to get [teen name] vaccinated or not to get [teen name] vaccinated with 
[vaccine]?” (decision). We created indicator variables for each component, separately for 
each vaccine. We coded responses as 1 if parents reported that the provider used that 
component of collaborative communication and 0 for all other responses (“no,” “don’t 
know,” or “refused,” or if parents reported that adolescents did not have visits for 
vaccinations).  
Separately for each vaccine, we classified providers’ communication styles into three 
categories to describe the degree of collaboration in patient-provider conversations. The first 
category (“minimal” collaboration) included parents who reported that providers did not 
engage in information exchange. The second category (“moderate” collaboration) included 
parents who reported that providers engaged in information exchange and one additional 
component of collaborative communication, i.e., either deliberation or decision.  The third 
category (“optimal” collaboration) included parents who reported that providers engaged in 
all three components of collaborative communication. 
Parents with missing data on at least one communication item for a given vaccine 
were excluded from analysis of outcomes for that vaccine. We retained them in analyses of 
vaccination outcomes for which they provided complete data. 
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Control variables. In addition to the main study variables, analyses controlled for 
adolescents’ age at the time of the interview (range: 13-17 years), adolescents’ sex (male or 
female), and adolescents’ insurance states (private health insurance or not). We also 
examined several other sociodemographic variables (e.g., adolescents’ race/ethnicity, 
mothers’ education level, number of children in the household); these factors were not 
associated with vaccination in bivariate analysis, so we excluded them from multivariate 
models. Analyses involving HPV vaccination excluded male adolescents because of the low 
prevalence of vaccine initiation (1.4%) in 2010.64  
Because we sought to isolate the effects of communication style on vaccine uptake, 
analyses also controlled for provider recommendation for each adolescent vaccine. Previous 
studies have demonstrated the strong influence of provider recommendation on vaccine 
uptake,6 including for this sample.70 For each adolescent vaccine, we coded participants as 1 
if they received a provider’s recommendation and 0 for all other responses (“no,” “don’t 
know,” or “refused”).  
Vaccination status. NIS-Teen measured receipt of Tdap, meningococcal vaccine, and 
HPV vaccine and verified it with providers’ reports. We classified adolescents as having 
received each vaccine if their healthcare providers verified administration in the mailed 
questionnaire. For HPV vaccine, we measured initiation (i.e., receipt of at least 1 dose) of the 
3-dose series, following the operationalization in our previous studies26,88,136 and in the 
CDC’s publications using NIS-Teen data.64 
Statistical Analysis 
To test the proposed hypotheses, we used multivariate logistic regression models to 
examine the association between vaccination and school entry requirements, communication 
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style, and their interaction, controlling for demographics and provider recommendation. We 
ran separate models for each vaccination outcome (coverage for Tdap, meningococcal 
vaccine, and HPV vaccine). We used Wald tests to examine the joint effects of the 
interaction terms in each model. If the Wald test indicated statistically significant 
moderation, we probed the interactions post-hoc to estimate the prevalence of vaccination 
according to communication style, separately for states with and without school entry 
requirements. If the Wald test did not indicate statistically significant moderation, we 
dropped the interaction terms and reran the model. 
A supplementary analysis analyzed potential carry-over effects by examining whether 
the relationship between communication style and receipt of meningococcal and HPV 
vaccines varied depending on states’ requirements for Tdap vaccination, which are the most 
common requirements across states. We used multivariate logistic regression models for each 
vaccination outcome consisting of Tdap vaccination school entry requirements, collaborative 
communication type for the vaccination outcome, and interaction terms for these two 
variables. We followed the procedures described above for evaluating moderation. 
All analyses were conducted in SAS version 9.2 (Cary, NC). Statistical tests used a 
two-tailed critical p value of .05. Analyses controlled for clustering of observations within 
states and incorporated survey weights provided by NIS-Teen to account for non-equal 
probability of selection. Below, we report unweighted frequencies and weighted proportions. 
Results 
Adolescents were nearly evenly split between male (52%) and female (48%) (Table 
7). Most adolescents were non-Hispanic white (60%), and 61% had private health insurance. 
Vaccination coverage among this sample was similar to the 2010 coverage for the entire 
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population:64 73% of adolescents had received Tdap, 66% had received meningococcal 
vaccine, and 49% of female adolescents had received at least 1 dose of HPV vaccine.  
Thirty-two states had Tdap vaccination school entry requirements in effect by the fall 
semester of 2010; 60% of participating adolescents lived in these states, with the remaining 
adolescents in states without Tdap vaccination policies. Thirty-four percent of parents 
reported that providers used a minimally collaborative style in conversations about Tdap, 
21% reported moderate collaboration, and 46% reported optimal collaboration. In 
multivariate analysis, Tdap vaccination was higher in states with school entry requirements 
compared to other states (odds ratio [OR]=1.22, 95% confidence interval [CI]=1.02, 1.45; 
p<.05) (Table 8). In addition, Tdap vaccination was higher when providers used a moderately 
collaborative style compared to minimally collaborative (OR=1.50, 95% CI=1.09, 2.05; 
p<.05) (Figure 12; Table 8).  
Ten states had meningococcal vaccination requirements; 25% of adolescents lived in 
these states. Forty-six percent of parents reported that providers used a minimally 
collaborative style in conversations about meningococcal vaccine, 14% reported moderate 
collaboration, and 40% reported optimal collaboration. In multivariate analysis, 
meningococcal vaccination was higher in states with school entry requirements compared to 
other states (OR=1.89, 95% CI=1.56, 2.30; p<.05) (Table 8). In addition, meningococcal 
vaccination was higher when providers used an optimally collaborative style compared to 
minimally collaborative (OR=1.63, 95% CI=1.22, 2.18; p<.05) (Figure 12; Table 8).  
Two states had HPV vaccination requirements; 2% of female adolescents lived in 
these states. Twenty-three percent of parents of female adolescents reported that providers 
used a minimally collaborative style in conversations about HPV vaccine, 24% reported 
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moderate collaboration, and 53% reported optimal collaboration. In multivariate analysis, 
HPV vaccination did not differ in states with versus without school entry requirements 
(Table 8). However, HPV vaccination was higher when providers used a moderately 
(OR=1.68, 95% CI=1.00, 2.84; p<.05) or optimally (OR=1.86, 95% CI=1.42, 2.42; p<.001) 
collaborative style compared to minimally collaborative (Figure 12; Table 8).  
For each vaccination outcome, vaccination school entry requirements and 
communication style did not interact in their association with the respective vaccines (all 
p≥.14). Supplementary analyses that examined the interactive effects of Tdap school entry 
requirements and collaborative communication type on uptake of meningococcal and HPV 
vaccines found no evidence of an interactive effect of these variables on either outcome (both 
p≥.41).  
Conclusion 
In a nationally-representative sample of U.S. adolescents, we found evidence of 
independent effects of vaccination school entry requirements and provider communication 
style on uptake of routine adolescent vaccines. Requirements for Tdap and meningococcal 
vaccination were associated with higher vaccination coverage, while requirements for HPV 
vaccination were not associated with differences in coverage. Patient-provider conversations 
that included all three components of Charles and Gafni’s framework for collaborative 
communication100,101,133 were associated with increased odds of meningococcal and HPV 
vaccination compared to conversations with fewer components. However, these two 
variables did not interact to predict vaccination. 
Generally, our results supported Hypothesis 1: Compared to other states, vaccination 
was more common in states with school entry requirements for Tdap and meningococcal 
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vaccine. Tdap vaccination requirements were associated with a 5% absolute increase in 
coverage (from 70% to 75%), and meningococcal vaccination requirements were associated 
with a 14% absolute increase in coverage (from 63% to 77%). These state policies may 
normalize adolescent vaccination and make it the default behavior.48,49 Interestingly, HPV 
vaccination requirements had no effect on HPV vaccination coverage. This finding could 
reflect resistance to HPV vaccination requirements and widespread use of liberal opt-out 
clauses in these policies.42 Together, these results provide support for Tdap and 
meningococcal vaccination school entry requirements as a public health intervention to 
increase adolescent vaccination coverage. However, states considering HPV vaccination 
requirements should take steps to ensure public acceptance or adopt less liberal opt-out 
clauses to increase the possibility that these policies lead to increases in coverage. 
In contrast to previous studies, we did not find that Tdap school entry requirements 
were associated with increased meningococcal or HPV vaccination coverage. We examined 
the influence of Tdap policies in a national, cross-sectional sample in 2010, versus 
Kharbanda and colleagues,51 who conducted a pre/post study in one state from 2006 to 2008, 
and Dempsey and colleagues,52 who conducted a national study in 2009 using a measure of 
school entry requirements that collapsed policies for Tdap and the tetanus and diphtheria 
(Td) vaccines. As Tdap school entry requirements have become more common, their 
influence on coverage levels for other vaccines may have been attenuated. Further studies are 
needed to investigate the longitudinal effects of Tdap school entry requirements on 
meningococcal and HPV vaccination in a national context across multiple years. 
We examined competing hypotheses for the direction of the relationship between 
collaborative provider communication style and uptake of adolescent vaccines. We found 
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support for Hypothesis 2a in that more collaborative communication styles were positively 
associated with vaccination coverage. Parents who reported that providers used optimal 
levels of collaboration were more likely to have adolescents who received meningococcal 
and HPV vaccines compared to parents who reported that providers used minimal 
collaboration (the difference for Tdap vaccination approached statistical significance). These 
findings provide preliminary empirical support for the role of shared decision making in 
improving healthcare outcomes,103,106 but intervention studies are needed to establish a causal 
association.  
Finally, our results did not support Hypothesis 3, that the health policy context would 
moderate the relationship between communication and vaccination. These findings suggest 
that providers’ use of a collaborative communication style was associated with higher levels 
of vaccination regardless of states’ school entry requirements. That is, even when parents had 
strong motivators for vaccination (i.e., school entry requirements), communication style was 
still associated with vaccination outcomes. Many previous studies have suggested additional 
training for primary care providers in how to engage parents and patients in discussions about 
vaccines,33,69,70,74 and our results underscore the importance of collaboration in these 
conversations, regardless of the policy context. Future studies should evaluate interventions 
to train physicians in collaboratively communicating with parents about adolescent vaccines 
while acknowledging state policies that require vaccination.  
Descriptively, the difference between coverage across communication styles is more 
pronounced for HPV vaccine than for meningococcal vaccine, which in turn is more 
pronounced than for Tdap; it appears that the effects of communication style are larger for 
vaccines for which fewer states have adopted fewer school entry requirements. However, 
93 
other policies related to vaccination, such as requiring schools to disseminate information 
about vaccines or allowing for non-medical exemptions from school entry requirements, may 
influence these relationships. Future studies should examine the effects of these policies. 
Study strengths include a large, nationally representative sample, allowing us to 
evaluate the effects of both policy and interpersonal factors on adolescent vaccination. The 
provider-verified adolescent vaccination records give us confidence in the validity of our 
dependent variable. Limitations include the cross-sectional nature of this analysis, which 
precluded our ability to draw causal inferences about the proposed relationships. Another 
limitation is that the data come from the 2010 NIS-Teen questionnaire. In the intervening 
years, vaccination coverage has increased, 15 more states have adopted Tdap vaccination 
requirements, and 10 states have adopted meningococcal vaccination requirements.37 In 
addition, the CDC began recommending routine administration of HPV vaccine to both 
female and male adolescents.15 As a result, the context in which vaccination takes place now 
is different than in 2010, yet we have no reason to believe the relationships described in this 
study have changed. The small sample size of adolescents in states with HPV vaccine school 
entry requirements (just over 2% of the female sample) reduced our statistical power for that 
analysis. Additionally, vaccination school entry requirements were not randomly distributed 
across states, potentially introducing some bias in the analyses involving this variable. 
Finally, due to the constraints of secondary data analysis, the minimally collaborative 
communication category combined several conceptually distinct conversation styles. That is, 
we could not distinguish between parents whose conversations with providers included 
absolutely no discussion of vaccines from others who had very limited conversations, 
including encounters in which (1) parents requested vaccines without prompting from their 
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provider, or (2) providers asked for consent to vaccinate without providing any information. 
However, even if this category combined several types of conversations, the comparison with 
other communication styles serves to isolate the effects of truly collaborative communication. 
In addition, these measures only captured parents’ perceptions of communication, not the 
providers’; to the extent that these perceptions diverge, the effects of communication style on 
vaccination may vary. Items began with a stem stating “At visits for made for [teen’s name]’s 
vaccinations…” and parents may have interpreted that to exclude conversations during 
healthcare visits that did not exclusively focus on vaccination (e.g., sick visits). Future 
studies are needed to further parse out different communication styles and their unique 
effects on vaccination. 
In conclusion, uptake of adolescent vaccines was higher in states with school entry 
requirements for Tdap and meningococcal vaccines but not HPV vaccine and for adolescents 
whose providers employed a collaborative communication style. The health policy context 
did not modify the association of provider communication style with vaccination coverage. 
Because states’ policies and providers’ communication styles had independent associations 
with vaccination, public health programs may be able to use either or both of these 
approaches to improve coverage with adolescent vaccines.  
Addendum 
In addition to the procedures described in this chapter, I originally proposed analyses 
of the effects of Tdap policies on adolescent vaccination. I have summarized or excluded 
these results from the manuscript for the sake of simplicity and because they were mostly 
null findings, but I have described them in this section. 
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In addition to their main effects on Tdap vaccination, school entry requirements for 
Tdap vaccine have also demonstrated positive associations with increased levels of HPV 
vaccination coverage.52 These carry-over effects likely arise due to concomitant 
administration of HPV vaccine during the same healthcare encounter that adolescents receive 
Tdap.15 We hypothesized that uptake of HPV vaccine would be higher in states with Tdap 
requirements than states without such requirements. In addition, we hypothesized that 
concomitant vaccination (HPV and Tdap vaccines) would be higher in states with Tdap 
requirements than states without such requirements. 
Further, we hypothesized that the association between providers’ communication 
style and vaccination may vary depending on whether a state has a Tdap school entry 
requirement. Because these requirements frame Tdap vaccination and not HPV vaccination 
as a default behavior,48,49 the role of providers’ communication style may become 
comparatively more influential in states with Tdap requirements compared to states without 
Tdap requirements. 
In addition to the measures described previously, we measured concomitant uptake of 
Tdap and HPV vaccines. We examined the reported dates of vaccine administration from the 
questionnaires mailed to healthcare providers as part of NIS-Teen. If administration of both 
Tdap and HPV vaccines occurred on the same day, we coded participants as receiving these 
vaccines concomitantly; we coded all other participants as not receiving these vaccines 
concomitantly. We excluded male adolescents from analysis of concomitant uptake of these 
vaccines. 
 We followed the procedures described here for examining the main and interactive 
associations of Tdap school entry requirements and provider communication style with 
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uptake of HPV vaccine and concomitant uptake of Tdap and HPV vaccines. That is, we 
conducted multivariate logistic regression including terms for both independent variables and 
their interaction. We used Wald tests to examine the statistical significance of the joint 
effects of the interaction terms in each model. If the Wald tests reflected a statistically 
significant interaction of these variables in their association with vaccination, we conducted 
post-hoc tests to probe the prevalence of vaccination in different provider communication 
categories separately for states with and without Tdap requirements. If the Wald test did not 
reflect a statistically significant interaction, we dropped these terms from the model and reran 
the multivariate logistic regression. 
As indicated above, HPV vaccination did not vary for states with or without Tdap 
vaccine school entry requirements (Supplemental Table S2). However, HPV vaccination was 
higher for adolescents of parents who reported that providers used a moderately (OR=1.71, 
95% CI=1.01, 2.91; p<.001) or optimally (OR=1.88, 95% CI=1.44, 2.47; p<.001) 
collaborative communication style, compared to minimally collaborative. These factors did 
not interact in their association with HPV vaccination (p=.41). 
Concomitant uptake of Tdap and HPV vaccines did not vary for states with or without 
Tdap vaccine school entry requirements (Supplemental Table S2). In addition, concomitant 
vaccination did not vary across providers’ communication styles in conversations about Tdap 
or in conversations about HPV vaccine. These factors did not interact in their association 
with concomitant vaccination (Tdap requirement by Tdap communication style: p=.43; Tdap 
requirement by HPV vaccine communication style: p=.25). 
Contrary to our hypotheses, Tdap vaccine school entry requirements were not 
associated with carry-over increases in adolescent vaccination, either for uptake of HPV 
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vaccine or for concomitant uptake of Tdap and HPV vaccines. In addition, providers’ 
communication style did not interact with Tdap requirements in their association with 
vaccination.  
As discussed previously, one study demonstrated an elevated HPV vaccination 
coverage level for states with Tdap vaccine school entry requirements compared to other 
states;52 however, that study examined the joint effects of policies for Tdap and the tetanus 
and diphtheria (Td) vaccines in place by Fall 2009. In contrast, our study examined the 
effects only of policies for Tdap that were in place Fall 2010. The secular trend in HPV 
vaccination coverage between 2009 and 2010 (increasing from 44% to 48%)64 may have 
diluted the effects of Tdap requirements on vaccination. Alternatively, narrowing the 
independent variable from Td/Tdap policies to Tdap policies only may have reduced some of 
the statistical power to detect a difference across states. For either explanation, the results 
imply that Tdap vaccine school entry requirements do not have a carry-over association with 
HPV vaccination in this cross-sectional study. 
Concomitant uptake of Tdap and HPV vaccines did not vary across states with or 
without Tdap vaccine school entry requirements. Because we hypothesized that concomitant 
vaccination was the mechanism connecting Tdap requirements with HPV vaccination 
coverage and we did not find a main effect of the relationship between these two variables, 
the lack of a statistical association between Tdap requirements and concomitant vaccination 
is not surprising. Although Tdap requirements were associated with increased Tdap 
vaccination, they did not appear to change parents’ and adolescents’ behaviors around HPV 
vaccination. 
98 
In addition, we found no effects of communication style on concomitant vaccination, 
either as a main effect or in interacting with Tdap vaccine school entry requirements. The 
lack of a statistically significant finding in this analysis may be related to vaccine hesitancy. 
Providers may be able to use a collaborative communication style to persuade vaccine-
hesitant parents and adolescents to receive a single vaccine, but they may be extremely 
resistant to concomitant vaccination regardless of communication style. Further, these 
families may acquiesce to Tdap vaccination to comply with a state policy, but a provider’s 
communication style may have no impact on their reluctance to consent to a second 
vaccination. Additional studies are needed to integrate vaccine attitudes (an intrapersonal 
factor) into this analysis of patient-provider communication (an interpersonal factor) and 
school entry requirements (a policy-level factor). 
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Table 7. Characteristics of Participants and Their Children  
Parental Attitudes Module, National Immunization Survey (NIS)-Teen, 2010. 
  Total Sample Male Female 
  n (%) n (%) n (%) 
Total          9,021             4,709  51.8          4,312  48.2 
Child characteristics 
Age             
   13          1,824  19.1             961  19.4             863  18.8 
   14          1,859  19.4             933  19.2             926  19.7 
   15          1,836  20.9             969  20.4             867  21.5 
   16          1,877  21.7             997  22.9             880  20.4 
   17          1,625  18.9             849  18.1             776  19.7 
Race/ethnicity             
   Hispanic          1,152  18.2             596  19.5             556  16.7 
   Non-Hispanic white          6,196  59.5          3,240  58.5          2,956  60.6 
   Non-Hispanic black             928  14.8             481  14.6             447  15.1 
   Other             745  7.5             392  7.4             353  7.6 
Private insurance             
   Yes          6,100  61.0          3,190  60.1          2,910  62.0 
   No          2,921  39.0          1,519  39.9          1,402  38.0 
VFC-eligible             
   Yes          2,663  34.8          1,399  35.2          1,264  34.5 
   No          6,358  65.2          3,310  64.8          3,048  65.5 
Preventive check-up in last 
year             
   Yes          7,737  85.0          4,013  83.5          3,724  86.6 
   No          1,284  15.0             696  16.5             588  13.4 
Well child check-up at age 11-
12             
   Yes          6,755  88.8          3,518  88.0          3,237  89.7 
   No             861  11.2             462  12.0             399  10.3 
Parent  characteristics 
Relationship of respondent to 
teen             
   Mother/female guardian          7,200  76.8          3,699  74.0          3,501  79.7 
   Father/male guardian          1,413  16.7             795  19.0             618  14.2 
   Other             408  6.5             215  7.0             193  6.0 
Mother's age             
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   ≤ 34 years             646  7.7             339  7.8             307  7.7 
   35-44 years          3,655  44.3          1,931  44.6          1,724  43.9 
   ≥ 45 years          4,720  48.0          2,439  47.6          2,281  48.4 
Mother's education level             
   Less than 12 years             781  12.0             404  12.9             377  11.0 
   12 years          1,856  26.3             984  26.4             872  26.1 
   More than 12 years, non-
college grad          2,623  26.1          1,341  25.1          1,282  27.2 
   College graduate          3,761  35.6          1,980  35.6          1,781  35.7 
Household characteristics 
Region             
   Northeast          1,850  18.2             959  18.1             891  18.4 
   Midwest          1,953  21.3             990  20.5             963  22.1 
   South          3,285  36.7          1,749  37.3          1,536  36.0 
   West          1,933  23.8          1,011  24.1             922  23.5 
Urbanicity             
   Metro          6,971  84.2          3,661  83.6          3,310  84.9 
   Non-metro           2,050  15.8          1,048  16.4          1,002  15.1 
Annual income             
   Below poverty level          1,296  18.4             675  18.9             621  18.0 
   Above poverty level, 
≤$75,000          3,493  38.5          1,839  39.2          1,654  37.8 
   Above poverty level, 
>$75,000          3,872  37.4          2,012  35.9          1,860  39.0 
   Unknown             360  5.7             183  6.1             177  5.3 
Number of children in 
household             
   1          3,567  31.6          1,886  31.7          1,681  31.5 
   2-3          4,612  55.7          2,404  55.0          2,208  56.5 
   4 or more             842  12.7             419  13.3             423  12.0 
 
Note. We present unweighted n’s and weighted percentages. 
 
 Table 8. Associations of Vaccine School Entry Requirements and Collaborative Communication Style with Adolescent Vaccination 
Coverage 
  Model 1: Model 2: Model 3: 
  Tdap     Meningococcal vaccine    HPV vaccine1 
  n/N % OR 95% CI n/N % OR 95% CI n/N % OR 95% CI 
Vaccine school entry 
requirement                         
   No 2,546/3,803 70.2 (ref) 4,418/6,818 63.2 (ref) 2,105/4,155 49.0 (ref) 
   Yes 4,006/5,218 74.7 1.22 (1.02, 1.45)* 1,757/2,203 76.8 1.89 (1.56, 2.30)* 86/157 47.1 1.17 (0.57, 2.41) 
Collaborative 
communication style                         
   Minimal 1,965/3,002 66.6 (ref) 2,068/3,930 55.2 (ref) 257/928 25.1 (ref) 
   Moderate 1,207/1,621 76.4 1.50 (1.09, 2.05)* 808/1,172 67.6 1.06 (0.78, 1.44) 333/976 35.5 1.68 (1.00, 2.84)* 
   Optimal 3,254/4,216 75.5 1.30 (0.99, 1.69) 2,834/3,621 78.4 1.63 (1.22, 2.18)* 1,506/2,220 66.3 1.86 (1.42, 2.42)** 
 
Note. School entry vaccination requirements and collaborative communication type referred to the specific vaccine in the model. 
Analyses controlled for adolescent age, sex, and insurance status, and receipt of a provider recommendation. Tdap = tetanus, 
diphtheria, and pertussis booster; HPV = human papillomavirus vaccine.  
1First dose among female adolescents only.  
*p<.05; **p<.001. 
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 Supplemental Table S2. Associations of Tdap Vaccine School Entry Requirements and Collaborative Communication Style With 
Adolescent Vaccination Coverage 
     HPV1    Tdap + HPV1 
n/N % OR 95% CI n/N % OR 95% CI 
Tdap vaccine school entry 
requirement 
   No 924/1,812 50.2 (ref) 246/1,812 16.6 (ref) 
   Yes 1267/2,500 47.7 0.86 (0.66, 1.10) 397/2,500 14.8 0.81 (0.58, 1.14) 
Collaborative communication style 
   Tdap 
      Minimal -- -- -- -- 195/1,331 15.5 (ref) 
      Moderate -- -- -- -- 125/783 17.8 1.21 (0.60, 2.45) 
     Optimal -- -- -- -- 307/2,104 15.2 0.98 (0.55, 1.73) 
   HPV vaccine 
      Minimal 257/928 25.1 (ref) 91/928 8.3 (ref) 
      Moderate 333/976 35.5 1.71 (1.01, 2.91)* 90/976 13.5 1.22 (0.45, 3.27) 
     Optimal 1,506/2,220 66.3 1.88 (1.44, 2.47)* 429/2,220 20.0 1.90 (0.83, 4.34) 
Interaction terms (p-value) 
   Tdap requirement x  
      Tdap communication style n/a 0.43 
   Tdap requirement x  
      HPV vaccine communication 
style       0.41       0.25 
 
Note. Analyses controlled for adolescent age, insurance status, and receipt of a provider recommendation. Tdap = tetanus, diphtheria, 
and pertussis booster; HPV = human papillomavirus vaccine. The estimates for relationships with HPV vaccination differ from those 
presented in Table 8 because the model controls for the interaction terms (which were excluded in the main table). 
1First dose among female adolescents only.  
*p<.001. 
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Figure 12. Association of collaborative communication style with adolescent vaccination 
coverage.  
Error bars show standard errors. 
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CHAPTER 8: DISCUSSION 
In the three studies that I present in this dissertation, I evaluated how school entry 
requirements changed the context for adolescent vaccination, particularly through 
concomitant administration. Although the studies were about three vaccines recommended 
for routine administration to 11- and 12-year-old adolescents (i.e., Tdap booster, 
meningococcal vaccine, and HPV vaccine), my focus was on HPV vaccination, given its low 
coverage118 and resulting missed potential for cancer prevention.110 In Chapters 5 and 6 (Aim 
1), I found that coverage for each adolescent vaccine, both singly and concomitantly, 
increased dramatically in the summer months compared to the rest of the calendar year. 
These increases partially explained the relationship between vaccination school entry 
requirements and coverage for both the vaccines targeted by those requirements as well as 
spillover onto other vaccines. In Chapter 7 (Aim 2), I found that vaccination school entry 
requirements and collaborative communication between patients and providers were both 
independently, positively associated with uptake of adolescent vaccines. Next, I describe 
overarching themes across these chapters, future directions for research, and strengths and 
limitations of these studies. 
Cycles in Adolescent Vaccination Matter 
Single and concomitant uptake of adolescent vaccines was 3 to 10 times as common 
at the peaks of the vaccination cycles compared to their troughs, using the ratio or highest to 
lowest incidence (see Chapter 5). These seasonal cycles were larger than other well-
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recognized patterns such as suicide (2 times as common in the summer as in the winter)53 or 
interest in smoking cessation (1.25 times as common on Mondays as the rest of the week).55  
These cycles have important implications for the timing of vaccine promotion 
interventions. Programs that are relatively brief, such as disseminating educational 
vaccination messages through radio spots, should occur in the late spring or early summer. 
These programs could impact recipients by the beginning of the summer increase in 
vaccination yet still be novel enough to be effective. In contrast, for programs that are more 
durable, such as altering a clinic’s electronic health record system, researchers should time 
their activities to occur earlier, perhaps in the winter or early spring, to ensure full adoption 
and sorting out implementation challenges well before the summer. 
Of particular interest to the study of HPV vaccination are the cycles of concomitant 
vaccination for HPV vaccine alongside either Tdap or meningococcal vaccine. Recently, 
Stokley and colleagues109 illustrated the untapped potential of concomitant uptake for 
increasing HPV vaccination coverage: They found that if all the girls in the 2000 birth cohort 
received HPV vaccine during a healthcare visit in which they received another vaccine, HPV 
vaccine initiation would have surpassed 90%. Little is known about how families make 
decisions about concomitant vaccination, but previous studies have found that some parents 
are reluctant to consent to their children receiving more than one vaccine in a day.137,138 I 
reported in Chapter 6 that states with higher proportions of concomitant vaccination in the 
summer compared to the entire year had higher HPV vaccination coverage rates. If 
interventions that educate parents about the efficacy31,139 and safety15,109,139 of concomitant 
vaccination take place in the spring, they may lead to improvements in concomitant 
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vaccination among adolescents who are already seeking Tdap or meningococcal vaccination 
during the summer. 
School Entry Requirements Increase Targeted and Spillover Vaccination 
As demonstrated in Chapter 6 and in preliminary studies,47,51,52,112 state policies that 
required adolescent students to receive vaccines before a certain school year were associated 
with increases in coverage for the targeted vaccines, and the effect spilled over onto coverage 
for non-targeted vaccines. These states also had more pronounced summer increases in 
vaccination coverage than other states. However, in all states, regardless of whether or not 
they had school entry requirements, vaccination peaked in the summer. Alternative 
explanations beyond school entry requirements must account for some of the observed 
increases. One of the most likely explanations is that in summer months, when most children 
do not attend school, parents could more easily take their children to primary care clinics for 
preventive healthcare services than other times of the year. Future research should examine 
cycles in vaccination for adolescents who attend schools with non-traditional formats, such 
as year-round schools or home schools. 
School entry requirements may frame uptake of targeted vaccines as a default 
behavior.48 The default effect may increase behavioral engagement through at least three 
mechanisms: effort, or the burden associated with pursuing an alternative to the default 
behavior; norms, or the implied recommendation from policymakers and the descriptive and 
injunctive social norms about the behavior; and loss aversion, which makes the default seem 
more appealing.48  
In states with school entry requirements, the phenomenon of parents more easily 
seeking preventive care for adolescents in the summer months was likely compounded by the 
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effort explanation for default effects. That is, to the extent that school entry requirements 
situate vaccination as a behavioral default, the effort needed to seek an exemption 
discouraged parents and adolescents from non-participation. In parents’ decision making 
about vaccination, the ease of seeking care in the summer and the anticipated effort of 
seeking an exemption from a school entry requirement may have reinforced one another, 
thereby exaggerating the summer peaks in uptake of targeted vaccines. Alternatively, parents 
may have little time in the brief period at the start of the school year when school 
administrators are more available to complete the requirements for opting out of the school 
entry requirement.  
Additionally, summer peaks may vary by the ease of states’ exemption policies. For 
example, previous studies have examined the complexity of seeking a non-medical 
exemption from vaccination requirements, which can range from simply signing a waiver to 
reading online educational material to speaking with a healthcare provider to obtain a 
signature.123,140 If parents view receiving education from a healthcare provider as effortful 
and signing a waiver as not very effortful, they may be more likely to seek an exemption in 
the states with less effortful exemption procedures, leading to reductions in summer peaks in 
vaccination, a topic for future research to examine. 
For the increases in coverage for vaccines not targeted by school entry requirements, 
the norms explanation may account for more of the effect than the effort explanation.48 
School entry requirements carry an implied recommendation to vaccinate from 
policymakers.48 In addition, as vaccination becomes more common in a population, 
descriptive and injunctive norms around receipt of adolescent vaccines may become more 
positive. These pro-vaccination norms may generalize to the non-targeted vaccines. The 
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combination of these norms, along with the ease of getting a second (or third) vaccine during 
the same healthcare visit as the one targeted by a school entry requirement, may explain the 
elevated concomitant vaccination in the summer months observed in this dissertation. Future 
studies should parse out the explanations for the success of school entry requirements (e.g., 
effort, norms, and loss aversion), particularly in increasing the magnitude of summer peaks in 
adolescent vaccination coverage. 
Given the strong, positive relationships between vaccination school entry 
requirements and coverage, a next step to support HPV vaccination might be to encourage 
states to adopt more vaccination requirements for Tdap or meningococcal vaccine. However, 
as of Fall 2014, 47 states had adopted Tdap vaccination requirements and 20 had adopted 
meningococcal vaccination requirements.37 Very few states can institute new Tdap 
vaccination requirements, but even instituting a new meningococcal vaccination requirement 
may not be desirable for HPV vaccination. Interestingly, the possibility exists that states with 
school entry requirements for both Tdap and meningococcal vaccination may experience 
relative reductions in HPV vaccine coverage. That is, if adolescents must receive Tdap and 
meningococcal vaccines but HPV vaccine is optional, families may choose to only receive 
the two required doses and opt out of receiving HPV vaccine. I will continue to investigate 
the possibility of this phenomenon in the current dataset by testing the interaction between 
Tdap and meningococcal vaccination requirements. As a result, future possibilities for 
expanding on vaccination school entry requirements may involve focusing on enforcement of 
existing policies34,119,141 or in adopting HPV vaccine requirements.42,43,142 
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Provider Communication Style Correlates with Adolescent Vaccination 
In cross-sectional analyses, adolescents who received vaccines recalled that their 
providers used a more collaborative communication style than unvaccinated adolescents. 
This association held true regardless of the vaccination school entry requirements in the state 
where the adolescents lived. These findings are consistent with recommendations for 
collaborative patient-provider communication.100,134 Collaborative communication can offer 
parents and adolescents the opportunity to learn about vaccines (or the diseases they protect 
against). Parents commonly report needing more information as a reason that they do not 
have their adolescents vaccinated with HPV vaccine.91,143-145 However, to facilitate 
collaborative communication, healthcare providers need to be comfortable discussing HPV 
vaccination. Previous studies have demonstrated that providers are reluctant to bring up HPV 
vaccine,146,147 either due to unfamiliarity with the disease, anticipation of parental resistance, 
or hesitance in discussing sexual activity. Experimental trials are needed to understand both 
the optimal communication techniques for providers discussing adolescent vaccines and the 
best ways to teach providers to use these techniques. 
These results also have implications for the ethical literature around communication 
and decision making in primary care. Providers cannot administer adolescent vaccines 
without at least bringing them up to parents and patients,128 but the degree of collaboration is 
flexible. Many ethicists have suggested that collaborative communication is unnecessary for 
decisions involving healthcare interventions that (1) have considerable support among 
clinicians, (2) are safe, and (3) do not have alternatives that could accomplish the same 
protection.131,132,135 Generally, vaccinations fall in to this category, and one previous study 
demonstrated quite dramatic benefits of directive communication for uptake of childhood 
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vaccines.108 However, we found in this study that recollections of collaborative 
communication were positively associated with uptake, even in states with vaccination 
requirements. So although collaborative communication about vaccines may be unnecessary, 
I found that it was associated with vaccination outcomes, over and above the effects of 
vaccination school entry requirements.  
I used the Charles and Gafni framework for collaborative patient-provider 
communication in primary care100,101,133 to organize my analysis of communication and 
vaccination. This framework suggests that collaborative communication includes joint efforts 
from patients and providers in information exchange, deliberation, and decision about a 
particular healthcare option. I found that, most commonly, parents recalled that they engaged 
in all three of these processes with providers in discussions about adolescent vaccines 
(“optimal” collaboration: Tdap: 46%; meningococcal vaccine: 40%; HPV vaccine: 53%). Yet 
the second most common communication type involved minimal collaboration (Tdap: 34%; 
meningococcal vaccine: 46%; HPV vaccine: 23%). That the bulk of vaccination 
conversations fell into the two extremes of the communication continuum may reflect the 
genuine uncertainty that exists regarding the style that promotes vaccination. They may also 
reflect the differing conditions under which clinicians recommend vaccination: directive 
approaches may work well with patients seen for many years, but a collaborative approach 
may more often be necessary when meeting with new patients. Although collaborative 
communication has become popular in medical practice in the past decades, directive 
communication may be more efficient and effective. Resolving this uncertainty is important 
for supporting clinicians in delivering adolescent vaccinations. 
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In addition, the Charles and Gafni framework (as well as most other models of 
communication in primary care) may be insufficient for understanding healthcare decisions 
that involve more than two people. That is, current theories do not account for the influence 
of patient, parent, and provider in communication and decision making, instead focusing only 
on the parent and provider. Although parents are the primary decision makers in healthcare 
for their children, the adolescent can still influence the ultimate outcomes. Most providers 
would not vaccinate adolescents against their will, even with parents’ consent.148 Though 
adolescents often feel removed from parent and provider conversations around healthcare 
options,69,95,104 most adolescents reported that they did not want to make decisions about 
vaccinations without their parents.93 Indeed, half of parents indicated that their daughters 
were involved in HPV vaccination decisions either a moderate amount or a lot.149 In my own 
research, I have found that parents and adolescent sons share similar attitudes and beliefs 
about HPV vaccine, but they have some distinct motivations for actually receiving the 
vaccine (manuscript under review). The decision-making process among these three actors, 
i.e., the patient, parent, and provider, is complex, and additional theoretical consideration 
about the interplay of their beliefs and actions would provide valuable guidance in future 
analyses of communication and adolescent vaccination. 
Despite these findings, the retrospective, observational nature of these data does not 
allow me to make conclusions about the direction of the relationship between communication 
and vaccination. On the one hand, collaborative communication may increase receipt of 
vaccines by allowing providers to persuade parents of the value of vaccination. On the other 
hand, parents who consent to vaccination may have different recollections of the 
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communication techniques their providers used. More research is needed to discern the 
direction of this relationship. 
Strengths and Limitations 
Study strengths include the use of a large, high-quality data source. The National 
Immunization Survey (NIS)-Teen contains five years of data about almost 100,000 
adolescents across the United States.61 It is a nationally representative dataset that the CDC 
uses to calculate its official estimates of vaccination coverage and that the U.S. Department 
of Health and Human Services uses to measure progress toward the Healthy People 2020 
goals.27 NIS-Teen includes provider verification of adolescent vaccination status, increasing 
the reliability and validity of the measures of vaccination under study. Provider verification is 
crucial for studying HPV vaccination, because self-reported measures often underestimate 
actual uptake.150 NIS-Teen contains data for the entire period because the Advisory 
Committee on Immunization Practices introduced Tdap, meningococcal vaccine, and HPV 
vaccine.15 In my analyses, I used sampling weights to account for non-equal probability of 
selection into the survey and thus increase the generalizability of results to the entire 
population of U.S. adolescents. 
A second strength of these studies is the use of strong interdisciplinary methods to 
examine the phenomena of interest. Chapter 5 uses the Edwards method, an approach 
borrowed from demography that is the most commonly used technique for analyzing 
seasonality.56,68 I selected this method by reviewing the variety of analytic techniques used in 
studies of cyclical effects.56,151 Several possible techniques emerged, including the Lorenz 
curve, the Edwards method, Cave and Freedman’s approach, decomposition, or simultaneous 
modeling (e.g., ARIMA). I was able to eliminate some of these options based on the 
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constraints of the data (i.e., observations available for only 60 time points, which precluded 
analysis with decomposition or simultaneous modeling) and expectations about the form of 
the cyclical effects based on the pilot data from North Carolina (i.e., a curve with only one 
maximum and one minimum per year, which precluded analysis with Cave and Freedman’s 
approach). Of the remaining options, I discovered that the Edwards approach was not only 
the canonical technique for this sort of analysis but it would also provide me with rich data 
on the magnitude and timing of cyclical effects. Taken together, these advantages convinced 
me that the Edwards approach was the ideal analytic technique for examining cyclical 
patterns in adolescent vaccination.  
I used bootstrapping to test for mediated effects in Chapter 6, a cutting-edge 
technique recommended by methodologists.124 Bootstrapping is preferred over techniques 
such as the Sobel test or the Baron and Kenny approach to examining mediation because it 
has the most statistical power and it reduces the possibility of Type I errors.124 In addition, 
theories and frameworks informed the analytic plans, contributing to the larger body of 
scientific knowledge around default effects, patient-provider communication, and 
interactions across levels of the socioecological framework. 
A third strength that cuts across these studies is their novelty. Although concomitant 
vaccination is an incredibly important behavior for public health,109 very few empirical 
studies have investigated it. By describing some of the processes supporting concomitant 
adolescent vaccination, these studies will support future interventionists in developing 
programs to promote this behavior. In addition, Chapters 5 and 6 use longitudinal techniques 
to expand on previous studies of adolescent vaccination that mostly have implemented cross-
sectional study designs. My research helps disentangle the temporality of the relationships 
114 
between school entry requirements, seasonal patterns in vaccination, and population-level 
vaccination coverage. 
In terms of limitations, in all of the studies I was able to observe states’ vaccination 
school entry requirements. Although my longitudinal studies (i.e., Chapters 5 and 6) 
examined temporality in the study relationships, third variables such as norms may drive the 
observed effects. For example, Rhode Island is in the process of adopting a school entry 
requirement for HPV vaccine, but it already has the highest rates of HPV vaccination among 
all U.S. states.118 Because HPV vaccine enjoys wide acceptance among people living in 
Rhode Island, adopting a school entry requirement was possible, while in other states, 
adopting such a policy may not be feasible. Because states do not randomly determine 
whether they should adopt a vaccination school entry requirement, I could not eliminate non-
spuriousness in these relationships. A related limitation pertaining to school entry 
requirements was that I could not assess whether adolescents had moved to a different state 
in the time between vaccination and participation in NIS-Teen; although I evaluated school 
entry requirements in adolescents’ state of residence at the time of survey participation, 
surely the requirements in the state where adolescents lived at the time of vaccination would 
be more salient to the processes under study. 
A second limitation was reduced statistical power. Although the overall sample was 
quite large, analysis of monthly vaccination, within years and within states, was precluded by 
small cell sizes, especially for analyses of concomitant vaccination (which is by definition 
less common than uptake of individual vaccines). Dividing the sample among that many 
units posed too great a threat of deductive disclosure, and the National Center for Health 
Statistics (who reviewed my study plans and output) prohibited this analysis. As the NIS-
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Teen sample accumulates, in future years I may be able to conduct the Edwards analysis in 
individual states and years for concomitant vaccination. 
Third, the response rate for NIS-Teen is adequate but not optimal. Across the five 
study years, 73–85% of eligible households contacted by survey staff participated in the 
telephone interview. Of participating parents in these households, 72–77% consented to have 
NIS-Teen staff contact their adolescents’ healthcare providers. Providers returned mailed 
questionnaires for 76–85% of adolescents. Altogether, 44–49% of contacted eligible 
households had complete, provider-verified data on participating adolescents. NIS-Teen staff 
attempted to ameliorate biases introduced by non-response by releasing survey weights for 
the subset of adolescents with provider-verified data (these were the weights I used in 
weighted analyses), but some possibility of bias remains. 
In addition, the communication analysis faced additional limitations. Because of the 
retrospective, observational nature of the data, causal inference about the observed 
associations was not possible. I was not able to assess other beliefs or attitudes that may be 
pertinent to communication and vaccination such as vaccine hesitancy. Finally, the items 
under study did not assess whether more than one healthcare provider talked to parents about 
the adolescent vaccines, and thus I could not assess how these multiple conversations may 
have impacted vaccination. 
Future Directions for Research 
This dissertation research has inspired at least three lines of future research: delving 
deeper into factors that support concomitant vaccination, conducting more fine-grained 
analyses of the effects of different types of vaccine policies, and refining the study of 
communication style and vaccination. First, given the dearth of research on concomitant 
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vaccination, I am interested in evaluating the factors that predispose adolescents to this 
behavior. A preliminary step would be to establish the sociodemographic and healthcare 
correlates of receiving vaccines concomitantly, a study I could undertake with the NIS-Teen 
data. A next step would be to examine the influence of theoretically-informed constructs on 
concomitant vaccination (e.g., perceived likelihood of contracting a vaccine-preventable 
disease, a construct from the Health Belief Model that is associated with HPV vaccine 
acceptability86). These studies would support the development of interventions designed to 
promote concomitant vaccination and increase overall levels of coverage. 
Second, I am interested in exploring the variations in states’ vaccination policies and 
their implications for both patient-provider communication and cycles in vaccination. I used 
a dichotomous measure to capture the presence of states’ vaccination school entry 
requirements in Chapters 6 and 7, but other options exist, including measures of (1) 
attempted legislation, i.e., proposed vaccination policies that state legislatures may have 
opted not to adopt;38 (2) policies requiring schools to educate parents on vaccination but do 
not require vaccine uptake;52 (3) enforcement of vaccination requirements, given that in 
policy and in practice consequences for violating the requirement vary across states;34,119,141 
and (4) ease of exempting out of a vaccination requirement.123,140 All of these policies could 
have different effects on patient-provider communication and vaccination cycles.  
Third, I hope to update the study of patient-provider communication style and 
vaccination in Chapter 7. Given that these data came from 2010, when vaccination rates were 
lower than in 2015 and the Advisory Committee on Immunization Practices had not yet 
recommended routine HPV vaccination for adolescent males,15 these relationships may have 
changed. In addition, primary prospective data collection would have greatly strengthened 
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this study. The items used in this analysis did not match perfectly the theoretical constructs 
under study, and they did not create a conceptually distinct reference category. Parents 
responded to these items by recollecting healthcare encounters that could have occurred up to 
four years prior to the NIS-Teen interview (from 2006, when ACIP introduced Tdap,15 to 
2010, when data collection occurred). Revising and updating that study could provide more 
valid inferences about the effects of collaborative patient-provider communication on 
adolescent vaccination. 
Conclusion 
Concomitant adolescent vaccination has the potential to vastly improve coverage with 
vaccines that protect against tetanus, diphtheria, and pertussis; meningitis; and genital warts 
and cancers caused by human papillomavirus. In Chapters 5 and 6 (Aim 1), I demonstrated 
the large annual cycles in uptake of individual adolescent vaccines and in concomitant 
vaccination. These cycles existed across the United States, within states, and for each of the 
past several years, and they were even more dramatic in states with vaccination school entry 
requirements. Further, these summertime increases in vaccination were associated with 
improved vaccination coverage. In Chapter 7 (Aim 2), I reported that parents’ recollections 
of collaborative communication with providers in discussions about adolescent vaccines were 
associated with a higher likelihood of uptake regardless of states’ vaccination school entry 
requirements. Through this dissertation, I also pointed to potential future methods for 
increasing adolescent vaccination coverage, particularly through promoting concomitant 
administration. By anticipating and preparing for annual increases in vaccination during the 
summer months and exploring further the effects of providers’ communication styles when 
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discussing adolescent vaccines with patients and their parents, clinicians and public health 
researchers can make progress towards achieving widespread coverage with these vaccines. 
Footnote 
The research in this dissertation was conducted while the author was a Special Sworn 
Status researcher of the U.S. Census Bureau at the Center for Economic Studies. Research 
results and conclusions expressed are those of the author and do not necessarily reflect the 
views of the Census Bureau. All results have been reviewed to ensure that no confidential 
information is disclosed. 
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